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ABSTRACT
ENVIRONMENTAL AND GENETIC INFLUENCE ON COGNITION IN ALS-FTD
SPECTRUM DISEASE
Katerina Placek
Corey T. McMillan
Murray Grossman
Amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) are
earlier-onset, fatal neurodegenerative diseases that progressively rob affected
individuals of their cognitive faculties and their ability to move freely, produce
coherent speech, and be their former selves. Diagnosis precedes death by <10
years, and current interventions are limited to palliative or disease-slowing
therapies. Recent seminal research has revealed that ALS and FTD are
phenotypic extremes on a continuous spectrum with shared symptoms,
pathobiology, and genetics. Despite increased knowledge of ALS-FTD spectrum
disease, prognostication and therapeutic development are limited by immense
phenotypic heterogeneity. One source of this heterogeneity is cognition:
individuals across the ALS-FTD disease spectrum suffer varying degrees of
decline in cognition due to neurodegeneration in the frontal and temporal lobes.
Cognition is inextricably linked to functional ability and survival, and is thus a
promising candidate for a prognostic marker and therapeutic target. With this in
mind, the goal of my thesis work is to elucidate factors that influence the
heterogeneity of cognitive impairment and corresponding frontotemporal
neurodegeneration in ALS-FTD spectrum disease. I pursue this goal by studying
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clinical, demographic, genetic, anatomic, and biologic data from deeplyphenotyped patient populations and applying robust statistical approaches
including multimodal, nonparametric, and machine learning analyses. My work
demonstrates strong environmental and genetic contribution to cognition and
frontotemporal disease anatomy in ALS-FTD spectrum disease, and suggests
their importance to advancements in clinical care and therapeutic development.
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CHAPTER 1: INTRODUCTION
In this chapter, I summarize prior scientific contributions to the study of factors
influencing cognition in ALS-FTD spectrum disease. I begin by providing a broad
overview of ALS-FTD spectrum disease with a focus on shared clinical, biologic,
and genetic features. I then turn to the specific issue of heterogeneity in cognitive
impairment, and review preliminary evidence for environmental and genetic
influence on its presentation. I finally discuss how analytic approaches
incorporating multimodal data sources and nonparametric and data-driven
techniques can be used to study outstanding questions regarding environmental
and genetic influence on cognition in ALS-FTD spectrum disease.
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ALS-FTD SPECTRUM DISEASE
Amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) are
earlier-onset, fatal neurodegenerative diseases that progressively rob affected
individuals of their cognitive faculties and their ability to move freely, to produce
coherent speech, and to be their former selves. Diagnosis precedes death in
typically less than ten years, and currently-available treatments are only palliative
or serve to slow disease course. Historically, ALS and FTD comprised separate
areas of research due to their respective neurological classifications as diseases
of the motor system or of higher order cognition and behavior. These conditions
are modernly thought of as two extremes on a continuous ALS-FTD disease
spectrum rather than distinct neurodegenerative conditions due to seminal
research from the past two decades demonstrating considerable overlap in
clinical presentation, common underlying pathobiology and neuroanatomy, and
shared genetic architecture. In this section, I will first briefly review the classic
disease profiles of ALS and FTD, and then discuss key clinical, pathobiologic,
neuroanatomic,

and

genetic

evidence

for

the

existence

of

these

neurodegenerative conditions along a continuous disease spectrum.

Disease Profile of ALS
ALS, which is also referred to colloquially as Lou Gehrig’s disease in the United
States and as motor neuron disease (MND) in the European Union, is
characterized by progressive degradation of the voluntary motor system resulting
in paralysis, and ultimately death. Symptom onset occurs from ages 40 - 70 but
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is also noted in individuals in the 20s and 30s, and a recent meta-analysis found
that 1.75 (1.55-1.96)/100,000 people per year worldwide are newly affected
(Marin et al. 2017). Diagnosis requires clinically-evident symptoms of upper
motor neuron (UMN) degeneration (e.g. spastic tone, deep tendon reflex) and
clinical, neuropathological, or electrophysiological evidence of lower motor
neuron (LMN) degeneration (e.g. weakness, muscle atrophy) (Brooks et al.
2000). Symptoms can occur in bulbar or spinal musculature and on ipsilateral or
contralateral sides of the body. Because ALS is a progressive disease and
patients may come to clinical attention with a sub-clinical syndrome, the
internationally recognized El Escorial criteria provide four categories of ALS
based on diagnostic certainty: Suspected, Possible, Probable, or Definite ALS.
Worsening of neuromuscular function over time is accompanied by progressive
gray matter (GM) loss in the motor cortex and white matter (WM) degeneration in
the corticospinal tracts and corpus callosum as evident through magnetic
resonance imaging (MRI) and diffusion tensor imaging (DTI) (Foerster, Welsh,
and Feldman 2013; Bede and Hardiman 2018), although extra-motor
neurodegeneration is also observed. An estimated 10% of patients with ALS
have a family history of disease often associated with a genetic mutation in
C9ORF72 (Renton et al. 2011; DeJesus-Hernandez et al. 2011), SOD1 (D. R.
Rosen et al. 1993), or TARDBP (Kabashi et al. 2008; Sreedharan et al. 2008);
and a minority of patients (~10%) without a family history also have C9ORF72
mutations (Taylor, Brown, and Cleveland 2016). Disease mechanism in patients
with and without a genetic mutation is yet unknown; abnormal protein inclusions
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composed of TDP-43 are found post mortem in ~97% cases, with the remaining
showing fused in sarcoma (FUS) pathology associated with point mutations in
the FUS gene (~1%) or showing superoxide dismutase pathology associated with
point mutations in the SOD1 gene (Al-Chalabi et al. 2012). Death typically occurs
20 - 48 months from initial symptom onset (Chiò et al. 2009), and is most
frequently due to respiratory failure but can also result from other causes
including cardiac failure (Corcia et al. 2008; Gil et al. 2008; D. R. Rosen et al.
1993). Currently, Riluzole (brand name: Rilutek) and Edavarone (brand name:
Radicava) are the only two treatments for ALS approved by the Food and Drug
Administration (FDA), and have mild impact on disease course and nonspecific
mechanisms of action. Riluzole targets excitotoxicity as a purported cause of
neuronal death (Van Den Bosch et al. 2006), and its potential mechanisms of
action include the inhibition of glutamatergic transmission, inactivation of voltagegated sodium channels, and interference with events following transmitter
binding at excitatory amino acid receptors (Doble 1996). Meta-analysis of four
clinical trials indicate that Riluzole usage mildly prolongs survival by 2-3 months
(R. G. Miller et al. 2007). The exact mechanism of action of Edavarone is also
unknown, but its therapeutic effect of slowing the rate of progression of functional
motor disability is attributed to its antioxidative properties (Cruz 2018; Abe et al.
2014). Current clinical and preclinical therapeutic development for ALS includes
highly-specific antisense oligonucleotide (ASO) therapies for patients carrying
SOD1 mutation or C9ORF72 repeat expansion and formulation of viral therapies
(Ly and Miller 2018).
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Disease Profile of FTD
Profound and worsening impairments in higher-order cognition, language, and
social behavior comprise the predominant symptoms of FTD. FTD is named for
the cerebral loci of neurodegeneration – in the frontal and temporal lobes responsible for three main observed syndromes: behavioral variant FTD
(bvFTD), semantic variant primary progressive aphasia (svPPA), and nonfluent
agrammatic primary progressive aphasia (naPPA). Each syndrome has its own
diagnostic criteria, with executive deficits, personality change, and apathy
characterizing bvFTD (Rascovsky et al. 2011), and discrete impairments in word
comprehension

and

agrammatism

characterizing

svPPA

and

naPPA,

respectively (Gorno-Tempini et al. 2011). The bvFTD syndrome is roughly four
times more prevalent than naPPA or svPPA (Hogan et al. 2016). Age at
symptom onset ranges from 21-80 years, with most cases occurring between 4064, (Coyle-Gilchrist et al. 2016) and meta-analyses estimate incidence at 2.74.1/100,000 (Onyike and Diehl-Schmid 2013), making FTD the 2nd most common
form of dementia among individuals less than age 65. Clinical FTD syndromes
are distinguished by progressive patterns of atrophy observed through structural
MRI (Meeter et al. 2017). Early atrophy in the orbital and dorsolateral prefrontal
cortex, anterior cingulate cortex, and insula are observed in bvFTD (Pan et al.
2012), whereas early atrophy in the left anteroinferior temporal lobe are observed
in svPPA, and in the left inferior frontal cortex and insula in naPPA (GornoTempini et al. 2004). All three syndromes feature progressive atrophy over
disease course, with subcortical structures including the thalamus, basal ganglia,
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and amygdala increasingly involved in bvFTD (Devenney et al. 2015), and
increasing extent of left and right hemispheric atrophy in svPPA and naPPA
(Rogalski et al. 2011; Bonner, Ash, and Grossman 2010; Grossman 2010).
Around 30% of FTD patients have a family history of disease which can be
largely attributed to pathogenic mutations in C9ORF72, MAPT, and GRN
(Greaves and Rohrer 2019), although C9ORF72 mutations are also found in
<10% of sporadic cases (Majounie et al. 2012). FTD is pathologically
heterogeneous, and post-mortem study shows abnormal protein inclusions in the
brain tissue composed of pathologic forms of TDP-43 in ~45-50% of cases, Tau
in ~45% of cases, and fused-in-sarcoma (FUS) protein in <10% of cases (Irwin,
Cairns, et al. 2014). The underlying pathologic protein can only be ascertained
through association with a known pathogenic mutation (e.g. TDP-43 with
C9ORF72) or, in mutation-negative cases, upon autopsy (Irwin, Cairns, et al.
2014). Death can occur as rapidly as 2 years and as prolonged as 12 years after
initial symptom onset (Coyle-Gilchrist et al. 2016). There is no FDA-approved
therapy for FTD; current treatments are palliative in nature and include
antidepressant and antipsychotic medications for symptom management (Boxer
and Boeve 2007; Tsai and Boxer 2016). Current therapeutic development
includes ASOs directed towards patients carrying C9ORF72 repeat expansions
and MAPT mutations, adeno-associated virus (AAV) therapies directed towards
patients carrying GRN mutations, and monoclonal antibodies (mAb) targeting
pathologic Tau (Boxer et al. 2020).
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Clinical Features of ALS-FTD Spectrum Disease
While symptomatically distinct in canonical diagnoses, FTD and ALS co-occur
and their considerable phenotypic overlap confers clinically-observable evidence
for their existence along a continuous disease spectrum. Broad recognition of
phenotypic overlap between ALS and FTD is noted in scientific and medical
literature beginning in the 1980s and 1990s (Neary et al. 1990), however early
case studies dating to the 1920s provide the first known descriptions of
phenotypic overlap (Nitrini 2014). The earliest known report comes from France
in 1921, and describes a male patient with ALS who developed impaired
cognition late in disease course. Three years later, in 1924, Brazilian physicians
described a 25 year-old female patient who exhibited "absolute indifference to
everything around her" and whose “association of ideas was done extravagantly"
– now recognized as symptoms of apathy and executive dysfunction often
observed in bvFTD; they further noted that her health declined before her death
one year later, leaving her ultimately bed-ridden due to severe muscular atrophy.
Contemporary population-based studies indicate 10-15% of patients with
ALS meet criteria for a diagnosis of FTD and that nearly half manifest nondementing impairment in cognition and/or behavior consistent with extra-motor
frontal and temporal lobe neurodegeneration (Montuschi et al. 2015; Phukan et
al. 2012; Elamin et al. 2013; Beeldman et al. 2016). Importantly, these
impairments are not confounded by motoric disability, suggesting that
neurological function beyond the motor system is affected in ALS. Point
estimates of the proportion of the ALS patient population exhibiting behavioral
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dysfunction and impairments in discrete cognitive domains have historically
differed, due in part to the use of different neuropsychological screening tools.
Current estimates have improved due to the use of a validated, now widelyaccepted, screening instrument specifically designed to measure cognition,
language, and behavior in the context of debilitating motor impairment which is
inherent to ALS (Abrahams et al. 2014). Behavioral dysfunction occurs most
frequently in ~40% of patients, and 20-30% of patients show executive, verbal
fluency, and language impairments; impairments memory and visuospatial
function are less common, affecting only 9-12% of patients (Crockford et al.
2018). Importantly, comorbid FTD and the development of extra-motor
impairments in cognition, language, and/or behavior in patients with ALS are
associated with more accelerated functional decline (Elamin et al. 2013),
advanced disease stage, (Crockford et al. 2018) and shorter survival (Elamin,
Phukan, Bede, Jordan, Byrne, Pender, and Hardiman 2011a; Hu et al. 2013),
relative to motor-only ALS.
Relatively less is known about the development of ALS in patients with
initial FTD. Population-based studies report that 4-9%

of patients

with

FTD develop symptoms of ALS (Rosso, Donker Kaat, et al. 2003; Mercy et al.
2008; J. K. Johnson et al. 2005; Seelaar et al. 2007); however, few studies
specify the degree of UMN and LMN involvement, and other clinical descriptors
of ALS (e.g. site of symptom onset, El Escorial diagnosis) are lacking. A smaller
cohort-based clinical study including 38 FTD patients reported higher
percentages of FTD patients who also meet criteria for ALS (~13%) and a higher
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percentage of patients with FTD who show clinical evidence of minor motor
system dysfunction such as occasional fasciculations, mild wasting or weakness
(~30%) (Burrell et al. 2011); these differing estimates likely reflect sample
characteristics. Others have also reported similar proportions based on post
mortem evidence of motor neuron degeneration in patients diagnosed with FTD
during life (Josephs et al. 2006).
Formal diagnostic categories for the co-occurrence of ALS and FTD were
not established until 2013 with the so-called ‘Strong criteria’ for the diagnosis of
frontotemporal cognitive and behavioral syndromes in ALS (Strong et al. 2009).
Revised as of 2017 to incorporate additional language and social cognition
deficits (Strong et al. 2017), the Strong criteria now include four syndromes
collectively considered as ‘ALS frontotemporal spectrum disorder’: ALScognitively impaired (ALSci), ALS-behaviorally impaired (ALSbi), ALS-cognitivebehavioral impairment (ALSbci), and ALS-FTD. ALSci and ALSbi are diagnosed
based on discrete impairments in cognition (including verbal fluency or at least
two demonstrated executive or language impairments) or behavior (including
apathy, or at least two other behavioral symptoms), respectively, whereas
ALSbci captures individuals who fulfill criteria for both ALSci and ALSbi. The
diagnostic category of ALS-FTD is more phenotypically heterogeneous, and
applies to individuals with evidence of progressive deterioration of behavior or
cognition who also have either 1) at least three behavioral or cognitive symptoms
of bvFTD, 2) at least two behavioral or cognitive symptoms of bvFTD together
with loss of insight or psychotic symptoms, or 3) fulfillment of criteria for svPPA or
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naPPA.
No distinct classification criteria exist for motor neuron degeneration
symptoms in the context of FTD, and El Escorial classification is applied as for
patients with initial ALS. The labels ‘ALS-FTD’, FTD with motor neuron disease
(FTD-MND), and FTD-ALS are all used in the literature to categorize patients
with initial FTD who also show symptoms of ALS; here, I will use the term FTDALS to denote this category of patients. This term inherently describes a
heterogeneous group of patients who may have initial bvFTD, naPPA, or svPPA
followed by comorbid with symptoms of ALS, and indeed bvFTD-ALS, naPPAALS, and svPPA-ALS patients have all been clinically observed (Vinceti et al.
2019; Coon et al. 2011), although data on relative frequency are lacking. There is
evidence of motor phenotype and survival differences between FTD-ALS
phenotypic subgroups, such that in one study, language-dominant FTD-ALS was
associated with bulbar-onset motor symptoms and shorter survival in comparison
with bvFTD-ALS (Coon et al. 2011), consistent with shorter survival from
symptom onset in bulbar-onset ALS (Chiò et al. 2009).

Common Pathobiology of ALS-FTD Spectrum Disease
Patterns of neurodegeneration in ALS and FTD reflect differences in motoric,
cognitive-behavioral, and blended phenotypes, but typically involve a common
pathologic substrate and overlap in affected neuroanatomic regions link the two
diseases in pathobiology.
ALS and FTD frequently share a common underlying proteinopathy, with
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cytoplasmic inclusions predominantly composed of TDP-43, an acronym for
transactive response DNA-binding protein – 43 kiloDalton, found in ~97% of ALS
and ~50% of FTD cases post mortem (Neumann et al. 2006; Arai et al. 2006).
TDP-43 is encoded by the TARDBP gene on chromosome 1 and is ubiquitously
expressed in tissues throughout the body. In its non-pathologic state, TDP-43 is
localized to the nucleus where it serves to regulate transcription, stabilize RNA,
and process mRNAs for alternative splicing (Ratti and Buratti 2016). Researchers
have also demonstrated a role for TDP-43 in axonal outgrowth with particular
implications for motor neuron development (Fallini, Bassell, and Rossoll 2012).
Pathologic TDP-43 differs from normal TDP-43 in that it is mislocalized from the
nucleus to the cytoplasm, undergoing hyperphosphorylation and – in most, but
not all (E. B. Lee et al. 2017), cases – ubiquitination, which encourage its affinity
to aggregate into abnormal inclusions (Buratti and Baralle 2012). The exact
pathomechanism of TDP-43 inclusions is debated (E. B. Lee, Lee, and
Trojanowski 2011), and evidence for both loss of function and gain of function
mechanisms has been presented (Hergesheimer et al. 2019).
Though its pathomechanism remains unknown, TDP-43 pathology
demonstrates a key role in the neurodegenerative phenotypes across the ALSFTD disease spectrum. TDP-43 pathology is specified into five subtypes (A, B, C,
D, and E) based on ubiquitination, cortical distribution, and neuronal morphology,
and each subtype corresponds to particular clinical syndromes (Mackenzie et al.
2011; Mackenzie and Neumann 2017; E. B. Lee et al. 2017). For example, Type
A pathology features many neuronal cytoplasmic inclusions (NCIs) and short
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dystrophic neurites (DNs), predominates in cortical layer II, and is most
commonly observed in bvFTD and naPPA phenotypes (Mackenzie et al. 2011).
Type B pathology features moderate NCIs, few DNs, and distribution across all
cortical layers (Mackenzie et al. 2011). Type B pathology predominates in ALS
and in FTD with motor neuron degeneration, leading some to propose subtype
specification as an account for clinical overlap between ALS and FTD (Burrell et
al. 2016).
Disease staging systems for TDP-43 pathology in ALS and bvFTD
demonstrate neuroanatomic overlap in disease vulnerability and suggest the
sequential spread of pathology. In a pathological staging system based on post
mortem study of 39 bvFTD cases, TDP-43 pathology is proposed to disseminate
from the orbital frontal cortex, gyrus rectus, and amygdala caudally to the motor
cortex, and – most rarely - the visual cortex (Brettschneider et al. 2014). In a
similar staging system in 76 ALS cases, TDP-43 pathology is proposed to
disseminate sequentially from the motor cortex, brainstem motor nuclei, and
spinal motor nuclei rostrally to the prefrontal and temporal cortices, with rare
involvement of the hippocampus (Brettschneider et al. 2013); others have
additionally shown that extra-motor pathologic burden is more severe in cases
with clinical phenotypes of ALS-FTD and ALSci relative to ALS (Prudlo et al.
2016). The sequential involvement of anatomic regions itself suggests a
pathologic ‘spread’ underlying the course of ALS-FTD spectrum disease, and in
vitro and non-human studies indeed suggest evidence of cell-to-cell spread of
pathologic TDP-43 aggregates (Braak et al. 2013). Isolated pathologic
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aggregates spread cell-to-cell in vitro in a prion-like manner (Feiler et al. 2015;
Nonaka et al. 2013), and introduction of human pathologic TDP-43 in a mouse
model recapitulates sequential staging seen in human studies (Porta et al. 2018).
Together with staging studies in humans, this research indicates similar
vulnerability of the motor, frontal, and temporal cortices to TDP-43 pathology
across the ALS-FTD spectrum in an anatomically contiguous manner.

Shared Genetic Architecture of ALS-FTD Spectrum Disease
In addition to overlapping clinical phenotypes and common pathobiology, FTD
and ALS are further linked through a shared genetic architecture. This complex
architecture features pathogenic mutations occurring in familial and sporadic
forms of disease, as well as susceptibility loci that confer increased risk of ALSFTD spectrum disease including in cases negative for pathogenic mutations.
Before discussing pathogenic mutations and risk factors in the ALS-FTD
spectrum, it is necessary to clarify some key terminology. ‘Familial’ refers to the
occurrence of a disease in an individual with a family history of that, or a similar,
disease, and ‘sporadic’ refers to the occurrence of a disease in an individual with
no known family history. The distinction between familial and sporadic disease
may be subject to ascertainment bias due to differences in history-taking or
applied family pedigree criteria (Turner et al. 2017). An estimated 30% of FTD
cases and <10% of ALS cases occur in individuals with familial disease (Ferrari,
Manzoni, and Hardy 2019), with the remainder classified as apparent sporadic.
The phrases ‘familial disease’ and ‘genetic disease’ are often conflated in the
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literature, as the majority of familial disease can be attributed to a known
pathogenic mutation inherited in a Mendelian fashion. However, pathogenic
mutations can also occur in individuals with sporadic disease (i.e. no family
history of disease). The term ‘pathogenic’ is used to describe genetic mutations
that are capable of causing disease, whereas susceptibility loci describe allelic
variations that are associated with disease but not (or not yet) causally linked to
disease incidence. These loci are typically identified through genome-wide
association studies (GWAS), and in many cases consist of single base-pair
changes in the genome called single nucleotide polymorphisms (SNPs).
Pathogenic mutations in the same genes are found in individuals with
FTD, ALS,

and blended

ALS-FTD spectrum phenotypes.

Interestingly,

pathogenic mutations in TARDBP - the gene encoding TDP-43 - are rare (Van
Deerlin et al. 2008; Kabashi et al. 2008), observed in an estimated <1% of
familial and sporadic ALS (Turner et al. 2017) and even less frequently in
patients with FTD (Benajiba et al. 2009; Caroppo et al. 2016). Hexanucleotide
(GGGGCC) repeat expansions in the noncoding promoter region of C9ORF72 on
chromosome 9 are the most common genetic cause of both familial and sporadic
forms of disease across the ALS-FTD spectrum (Renton et al. 2011; DeJesusHernandez et al. 2011). A 2012 study of 4448 patients with ALS and 1425
patients with FTD reported that 37.6% of familial ALS and 25.1% of familial FTD
harbor C9ORF72 mutations, and that 7% of sporadic ALS and 6% of sporadic
FTD patients harbor C9ORF72 mutations (Majounie et al. 2012). Translation of
the hexanucleotide repeat yields five forms of dipeptide repeat proteins (DPRs)
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that aggregate to form intracellular inclusions (Mori et al. 2013), and have
demonstrated neuronal toxicity (Freibaum and Taylor 2017). Moreover,
C9ORF72 repeat expansions are causally associated with TDP-43 pathology
(Chew et al. 2015), and aggregated DPRs both induce and are induced by
intracellular aggregation of phosphorylated TDP-43 (Nonaka et al. 2018;
Solomon et al. 2018), suggesting a cumulatively synergistic pathology.
Several additional - although rare - pathogenic mutations in other genes
have also been causally associated with ALS, FTD, and blended ALS-FTD
spectrum phenotypes. These include mutations in coding for proteins including
sequestosome-1 (SQSTM1) (Le Ber et al. 2013), ubiquilin-2 (UBQLN2) (Synofzik
et al. 2012), optineurin (OPTN) (Pottier et al. 2015), coiled-coil-helix coiled-coilhelix domain containing 10 (CHCHD10) (Bannwarth et al. 2014), TANK binding
kinase 1 (TBK1) (Freischmidt et al. 2015), dynactin-1 (DCTN1) (Münch et al.
2005), cyclin-F (CCNF) (Williams et al. 2016), and TIA1 (TIA1) (Mackenzie et al.
2017). Interestingly, these rare mutations offer additional genetic insight into
molecular mechanisms of ALS-FTD spectrum disease and implicate cellular
waste disposal pathways, immune system signaling, and gene expression
regulation (Ferrari, Manzoni, and Hardy 2019).
Susceptibility loci further suggest shared genetic architecture along the
ALS-FTD disease spectrum. Many case-control GWAS have been separately
performed in ALS (Nicolas et al. 2018; van Es et al. 2009; van Es et al. 2007; van
Rheenen et al. 2016) and in FTD (Ferrari et al. 2014; Ciani et al. 2019). One
GWAS from 2010 focused on ALS-FTD disease spectrum phenotypes with
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confirmed TDP-43 pathology (N=515) and identified multiple SNPs near
TMEM106B mapping to a single linkage disequilibrium block on 7p21 (Van
Deerlin et al. 2010); however, this study was restricted to unrelated individuals
with mutations in GRN. A recent repeat of this GWAS approach in 517 unrelated
Caucasian patients who screened negative for GRN and other pathogenic
mutations associated with ALS-FTD spectrum disease identified additional SNPs
near C9ORF72, UNC13A, DPP6, and HLA-DQA2 (Pottier et al. 2019). A joint
meta-analysis of public GWAS data from 4,377 ALS patients and 435 pathologyproven FTD patients with TDP-43 also demonstrated shared genetic risk across
the ALS-FTD spectrum at SNPs near UNC13A and SPG8, with p values for the
locus near UNC13A increasing in significance after conditioning on C9ORF72
(Diekstra et al. 2014). More recently, novel approaches incorporating genomewide conjunction and conditional analyses studied the joint association between
discrete phenotypes along the ALS-FTD spectrum (ALS, FTD with TDP
pathology, sporadic FTD) and additional neurodegenerative phenotypes
(Alzheimer

disease,

corticobasal

degeneration,

Parkinson

disease,

and

progressive supranuclear palsy) (N=124,876), conditioning p values for identified
loci based on shared association with two or more phenotypes (Karch et al.
2018). Over 20 loci were identified, including at known loci (e.g. near UNC13A
and C9ORF72) and at novel loci (e.g. near NSF and ERGIC1). Additional
approaches further suggest that susceptibility loci may contribute to the genetic
architecture underlying the ALS-FTD spectrum disease in a polygenic manner,
though this was demonstrated in a population of healthy individuals from the UK
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Biobank study (Hagenaars et al. 2018).

Neuroanatomy of ALS-FTD Spectrum Disease
The lack of current neuroimaging biomarkers for TDP-43 pathology precludes
study of its anatomic distribution in vivo (Feneberg et al. 2018), but MRI and DTI
enable the in vivo study of neurodegeneration across the ALS-FTD spectrum and
suggests similar anatomic overlap as seen in post mortem study of TDP-43
pathology. Cross-sectional studies of patients grouped by diagnosis recapitulate
known disease neuroanatomy associated with ALS and FTD phenotypes (Omer
et al. 2017), and demonstrate anatomic overlap in the orbitofrontal and anterior
cingulate cortices, corticospinal tracts, and corpus callosum including between
ALS patients without clinically-evident cognitive impairment and bvFTD patients
(Crespi et al. 2018; Ferraro et al. 2018). Blended ALS-FTD disease spectrum
phenotypes

(e.g.

ALS-FTD,

ALSci,

FTD-ALS)

show

more

extensive

neurodegeneration relative to discrete ALS or FTD syndromes. For example, one
recent study of ALS in the context of language-variant FTD observed left
precentral gyrus GM atrophy in patients with naPPA-ALS in addition to canonical
naPPA-associated atrophy in the left inferior frontal gyrus, pars opercularis and
triangularis, and left temporal pole (Vinceti et al. 2019). ALSci and ALS-FTD
patients show increasing extramotor GM neurodegeneration in regions including
the inferior, middle, and superior temporal gyri, orbitofrontal cortex, superior
frontal gyrus, anterior cingulate cortex, and insula relative to frank ALS (Schuster
et al. 2014; Agosta et al. 2016), and WM damage extending beyond the
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corticospinal tracts and corpus callosum to include the uncinate and superior
longitudinal fasciculi (Sarro et al. 2011; Agosta et al. 2016).
MRI-based disease-staging systems and longitudinal neuroimaging
provide perhaps the most approximate insight into the spread of ALS-FTD
spectrum disease in vivo. DTI data from patients with ALS and from patients
bvFTD have been staged cross-sectionally and longitudinally according to
severity and extent of WM neurodegeneration and confirm anatomic patterns of
TDP-43 pathology staging systems (Kassubek, Müller, Del Tredici, Lulé, et al.
2018; Kassubek, Müller, Del Tredici, Hornberger, et al. 2018; Kassubek et al.
2014; Müller and Kassubek 2018). Others have staged cross-sectional
multimodal imaging data with neuropsychological evaluation to demonstrate
sequential

cognitive

involvement

corresponding

to

GM

and

WM

neurodegeneration in ALS, suggesting earlier-stage involvement of the middle
frontal cortex relating to executive impairment (Lulé et al. 2018). Longitudinal
study of GM atrophy in ALS, while inherently limited by shorter patient survival,
demonstrates progressive degeneration extending from the motor cortex rostrally
and inferiorly into frontotemporal regions, and to the thalamus and caudate
bilaterally (Menke et al. 2014). In FTD, longitudinal study of patients grouped by
clinical variant shows worsening of focal atrophy; for example svPPA show
greater percent atrophy changes in the left inferior temporal lobe relative to
bvFTD, whereas bvFTD show greater percent atrophy in the ventromedial
prefrontal cortex relative to naPPA (Lu et al. 2013).
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ENVIRONMENTAL AND GENETIC INFLUENCES ON COGNITION
Though a phenotypic spectrum, shared pathobiology and neuroanatomy, and
common genetic architecture demonstrate a robust link between ALS and FTD,
considerable heterogeneity between affected individuals precludes prognosis
and therapeutic development. One source of heterogeneity of particular clinical
importance is in cognition. Across the ALS-FTD spectrum, presence and severity
of impaired cognition is consistently linked to rapid functional decline (Elamin et
al. 2013), greater extent and severity of frontotemporal neurodegeneration
(Agosta et al. 2016), greater caregiver burden (Caga et al. 2019), and shorter
survival (Elamin, Phukan, Bede, Jordan, Byrne, Pender, and Hardiman 2011a;
Hu et al. 2013). In this section, I review existing evidence for influences of
environmental and genetic factors on impaired cognition, and discuss key
knowledge areas that are lacking.

Environmental Influences
Environmental modifiers of disease refer to factors external to the individual that
can influence facets of disease including incidence and phenotype. Numerous
and diverse environmental factors have been associated incidence of ALS-FTD
spectrum disease. These include the association of cigarette smoking, athletic
activity, environmental toxin exposure, and military service with increased odds
of ALS incidence (Sutedja et al. 2007; Veldink et al. 2005; Huisman et al. 2013;
Weisskopf et al. 2005; Bozzoni et al. 2016), and traumatic brain injury with
increased odds of FTD incidence in veterans (Kalkonde et al. 2012) and in
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sporadic FTD (Rosso, Landweer, et al. 2003). However, in terms of cognition,
identified environmental factors come from a narrower category and largely relate
to cognitive engagement over the lifespan.
The discovery of the relationship between cognitive engagement and
cognitive impairment comes from research on Alzheimer’s disease dementia by
Dr. Yaakov Stern, who coined this phenomenon ‘cognitive reserve’ (Stern 2002).
In a seminal series of work published in the 1990s, Dr. Stern demonstrated that
individuals with higher years of education or more cognitively-taxing occupations
had more advanced stages of Alzheimer’s disease as measured by rate of
memory decline (Stern et al. 1999), temporoparietal blood perfusion seen
through PET imaging (Stern et al. 1994), and survival (Stern et al. 1995). This led
to the theory that cognitively-stimulating lifetime experiences like education may
provide a ‘reserve’ that compensates for the neuropathological changes of
Alzheimer’s disease, thus delaying the onset of clinical manifestation. Both
functional

and

biologic

mechanisms

have

been

proposed

to

underlie

observations of cognitive reserve. Functional accounts posit that increased
frontal executive resources cultivated through lifetime cognitive engagement
allow compensation for medial temporal lobe disease. Neuroimaging studies are
most often cited as supporting functional accounts of cognitive reserve, and
include reports of increased frontal connectivity in highly-educated individuals
associated with attenuated memory decline, brain hypometabolism, and
hippocampal volume loss (Franzmeier et al. 2017; Pudas et al. 2018). Biologic
accounts referred to in the literature as ‘brain reserve’ propose that
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neuroanatomic differences might also underlie observations of cognitive reserve.
In support of this, one study in healthy elderly individuals demonstrate greater
frontoparietal GM volume related to higher levels of education (Solé-Padullés et
al. 2009).
Evidence for cognitive reserve has been also observed in FTD, but differs
in manifestation from Alzheimer’s disease. Primary atrophy in the frontal and
temporal lobes characterizes disease phenotypes across the ALS-FTD spectrum,
inherently compromising access to proposed frontal executive resources
hypothesized to facilitate functional compensation for neurodegeneration in
classic accounts of cognitive reserve. Research in patients with bvFTD supports
this idea, as more cognitively-demanding premorbid occupational status relates
to more rapid decline in executive function but not in semantic memory, a
cognitive domain that is relatively spared in patients with bvFTD (Massimo et al.
2019). Both higher occupational and educational attainment relate to lower
cerebral blood flow (Borroni et al. 2009) and lower glucose metabolism (Spreng
et al. 2011; Perneczky et al. 2007) in the frontal cortex in patients with bvFTD,
demonstrating compromised frontal lobe activity. Furthermore, cognitive
engagement is differentially associated with survival in FTD compared to
Alzheimer’s disease, with more cognitively-demanding premorbid occupation
relating to longer survival from symptom onset in bvFTD but shorter survival from
symptom onset in Alzheimer’s disease (Massimo et al. 2015).
While prior research has identified cognitive engagement as an
environmental contributor to cognitive impairment, several limitations necessitate
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further study to understand its influence in the ALS-FTD disease spectrum. First,
prior research on cognitive reserve in ALS-FTD spectrum disease have been
limited to a single phenotype – bvFTD – and explicitly excluded individuals with
motor symptoms. Thus, it is yet unknown whether this phenomenon extends to
influence cognition in patients with other ALS-FTD spectrum phenotypes
including ALS-FTD, svPPA, and naPPA. Furthermore, prior studies have not yet
explored structural brain integrity, or how cognitive reserve may mediate the
relationship between brain structure and cognitive impairment. These lead to the
following unanswered question in environmental influence on cognition in ALSFTD spectrum disease: how does cognitive reserve relate to structural
neuroanatomy and cognitive impairment in heterogeneous phenotypes across
the ALS-FTD spectrum?

Genetic Influences
Prior discussion of genetics in this introduction largely related to the incidence of
disease; however, accumulating evidence suggests genetic influence on
phenotypic heterogeneity in ALS-FTD spectrum disease. This includes earlier
age at disease onset, more rapid symptom progression, and shorter survival in
C9ORF72 mutation carriers relative to non-carriers (Byrne et al. 2012; Suh et al.
2015; Umoh et al. 2016; Irwin, McMillan, et al. 2014; Moore et al. 2020), and in
patients screening positive for SNPs near UNC13A (Chiò et al. 2013). Additional
evidence suggests that the relationship between genetics and phenotypic
heterogeneity in ALS-FTD spectrum disease extends to cognition and implicates
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both pathogenic mutations and SNPs.
In the context of ALS-FTD spectrum disease, the majority of research on
genotype-phenotype relationships in cognition has been focused on C9ORF72.
First, in addition to causal association with frank ALS, frank FTD, and varied
phenotypes along the ALS-FTD disease spectrum, C9ORF72 mutations increase
the likelihood that an ALS patient will develop symptoms of FTD. One populationbased study in the US (N=781) reported behavioral symptoms of FTD in 14.8%
of ALS patients who were carriers compared to only 1.7% of non-carriers (Umoh
et al. 2016), whereas another population-based study in Ireland (N=191) reported
behavioral symptoms in 50% of carriers compared to 12% non-carriers (Byrne et
al. 2012). C9ORF72 mutations are also linked to rate of cognitive decline across
the ALS-FTD spectrum, with one study showing more rapid decline on a verbal
fluency measure of executive function (Irwin et al. 2013) and another showing
more rapid decline in visuospatial and memory function in addition to executive
function (Mahoney et al. 2012). Psychiatric symptoms have also been reported in
C9ORF72 mutation carriers across the ALS-FTD disease spectrum (Snowden et
al. 2012; Devenney et al. 2017). Neuroanatomic differences in C9ORF72 carriers
relative to non-carriers are also widely observed both in vivo and post mortem. A
comprehensive literature review conducted in 2015 show heterogeneity of
findings across published studies of neuroimaging in C9ORF72 carriers likely
due to differences in clinical phenotype and disease stage (Prado et al. 2015).
However, studies accounting for these potential confounds show more extensive
extramotor GM and WM degeneration particularly in frontotemporal regions in
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ALS (Bede et al. 2013), which also correspond to cognitive impairment (Floeter
et al. 2016). Post-mortem, C9ORF72 mutation carriers display TDP-43 pathology
in the cerebellum and hippocampus, which are rarely observed in non-carriers
(Mackenzie, Frick, and Neumann 2014). Interestingly, the associations between
C9ORF72

mutation

status,

cognitive

impairment,

and

neuroanatomic

susceptibility appear to be epigenetically modulated: hypermethylation of the
C9ORF72 promoter shows evidence of neuroprotection in terms of cognitive
decline,

MRI

measures

of

structural brain

integrity,

and

post-mortem

neuropathologic burden (Russ et al. 2015; McMillan et al. 2015).
A small, yet growing body of evidence demonstrates that genetic influence
on cognition extends beyond study of known pathogenic mutations to also
include susceptibility loci. These include quantitative trait loci (QTL) analyses that
probe the association between a genetic locus and variation in a continuous,
rather than binary (e.g. having disease vs. not having disease), disease trait. A
SNP near TMEM106B originally identified as a susceptibility locus for TDP-43
pathology in GRN mutation carriers was found to relate to impaired cognition on
a task of executive function in patients with ALS (Vass et al. 2011). In bvFTD
patients, genotype-phenotype relationships are also observed. Risk genotype at
a SNP near the MOBP gene was found to associate with more severe WM
neurodegeneration in the corona radiata and superior and inferior longitudinal
fasciculi, more severe GM neurodegeneration in the precuneus and superior
temporal gyrus, and shorter survival from symptom onset in a mixed cohort of
sporadic, mutation-negative bvFTD patients with underlying Tau and TDP-43
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pathology (Irwin, McMillan, et al. 2014). In another study, SNPs near MAPT,
GRN, SORT1, and MOBP related to distinct WM neurodegeneration in the
superior longitudinal fasciculus and midbrain in sporadic, mutation-negative
patients with varying ALS-FTD spectrum disease phenotypes (McMillan et al.
2014). The majority of ALS-FTD spectrum disease occurs in the absence of a
family history disease or known pathogenic mutation, suggesting that the
susceptibility loci mentioned here, and others yet unexplored, may influence
variance in dementia for a larger proportion of ALS-FTD spectrum disease.
Here, I have discussed promising evidence for genetic influence on
cognition in the ALS-FTD spectrum, yet much work in this area remains. The
majority of prior work focuses on studies of individuals carrying C9ORF72 repeat
expansions, and research in mutation-negative individuals is considerably less
established. Many SNPs associated with incidence of ALS-FTD spectrum
diseases have been identified, yet few have been studied in regards to
quantitative or qualitative trait associations with cognition. Prior efforts to
characterize the quantitative disease associations with single SNPs have been
limited to the study of a single clinical phenotype or to the use of a single
research modality, and potential polygenic contribution to cognition in ALS-FTD
spectrum disease remains relatively unexplored. These lead to the following
unanswered questions: Do SNPs associated with risk of ALS-FTD spectrum
disease show quantitative-trait relationships with cognition and disease
neuroanatomy? Do they do so in a polygenic manner?
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MULTIMODAL, NONPARAMETRIC, AND MACHINE-LEARNING
APPROACHES
Thus far, I have described how ALS-FTD spectrum disease features complex
overlap in clinical, neurobiologic, anatomic, and genetic characteristics. I have
also reviewed prior literature in this field to identify outstanding research
questions pertaining to how heterogeneity in the cognitive status of affected
individuals may be shaped by environmental and genetic factors. In this section, I
turn to discuss how these research questions can be addressed, focusing on
multimodal, nonparametric, and machine learning approaches.
Research employing multimodal data involves the collection and analysis of
data from several, rather than single, sources. Deep phenotyping of patient
populations with ALS-FTD spectrum disease requires data from multiple, diverse
modalities,

including

clinical

evaluation,

demographic

information,

neuropsychological assessment, neuroimaging acquisition, genetic screening
and genome sequencing, and post mortem neuropathologic analysis (Toledo et
al. 2014). Each modality is able to characterize a specific and different facet of
the disease process. For example, neuropsychological assessments are used to
characterize and quantify cognitive impairment syndromes (Abrahams et al.
2014;

Strong

et

al.

2017),

structural

MRI

reveals

the

anatomy

of

neurodegeneration underlying patient syndromes (Menke et al. 2017; Meeter et
al. 2017), and neuropathologic and genetic study identify potential molecular
causes and modifiers of disease (Neumann et al. 2006; Renton et al. 2011;
DeJesus-Hernandez et al. 2011). The concurrent consideration of data from
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multiple modalities allows for a characterization of disease that extends beyond a
broad categorical diagnosis (i.e. clinical phenotype) to additionally describe the
collection of the finest details about the condition (i.e. endophenotype) (Irwin,
Cairns,

et

al. 2014). Multimodal approaches

are

critical to

establish

endophenotypes, for example, a patient with a clinical phenotype of ‘ALS’ could
be endophenotyped as ‘a mutation-negative patient with sporadic ALS who has
impaired executive function and structural MRI evidence of extramotor frontal
lobe neurodegeneration’. Endophenotypes, in turn, are critical for the
development and application of precision medicine therapies designed to target
specific aspects of disease (e.g. ASOs designed to target C9ORF72 repeat
expansions).
In addition to enabling deep endophenotyping, multimodal data collection
provides the opportunity to evaluate the reproducibility and robustness of
research findings across complementary, yet distinct, datasets. Data collection
from neurodegenerative patient populations suffers limitations in sample size and
is often inconsistent in protocol across research centers, thereby precluding
studies of direct reproducibility. Multiple modalities of data collected on the same
patient cohort or, alternatively, different modalities of data collected on
independent patient cohorts, offers a partial solution to this problem by increasing
the number of datasets a researcher can study. With an increased number of
datasets, researchers can assess the reliability of an observed effect and
evaluate whether differing sources of data converge on a common finding (Bachli
et al. 2020). For example, a genetic risk factor for cognitive impairment in ALS
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might be further evaluated in relation to in vivo frontotemporal neurodegeneration
through structural neuroimaging and post mortem burden of pathology.
Irrespective of modality, data collected from patients often violate
assumptions of statistical normality (e.g. homeoscedasticity) and thus make the
use of parametric statistical methods inappropriate for their analysis (Pett 2015).
Permutation-based tests are a class of nonparametric statistical methods that
test the null hypothesis by calculating the probability of observing an outcome in
the original data relative to random permutations of the data. Efficient
permutation methods have been adopted for usage in healthcare datasets,
including large and computationally-expensive neuroimaging and genetic
datasets (Winkler et al. 2014; Conneely and Boehnke 2007). These methods
have been previously employed to analyze both neuroimaging and genetic data
from patients with ALS-FTD spectrum disease (McMillan et al. 2015; McLaughlin
et al. 2017), suggesting their utility in further study of multimodal data from this
patient population.
In addition to nonparametric approaches, machine-learning has been
employed in the study of neurodegenerative disease (Dinov et al. 2016;
Hongming Li et al. 2019), including in bvFTD (Schroeter et al. 2014; Bachli et al.
2020) and in ALS (Grollemund et al. 2019; Hothorn and Jung 2014). Machine
learning uses computationally-powerful statistical techniques to make inferences
and predictions from large datasets and techniques have been developed for use
with single as well as multiple datasets (James et al. 2014). One machine
learning technique developed for the analysis of multimodal data is sparse
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canonical correlation analysis (sCCA). sCCA evaluates multivariate associations
between two data sets while prioritizing sparsity by penalizing variables that
contribute minimally to the statistical model (Witten, Tibshirani, and Hastie 2009;
Witten and Tibshirani 2009). Importantly, variable selection from sCCA is datadriven in nature, chosen through analysis rather than by a researcher. Recently,
sCCA was employed to identify SNPs associated with selective distributions of
GM and WM disease in FTD patients (McMillan et al. 2014), and to identify
compromised neuroanatomic networks related to executive, language, and
behavioral phenotypes in patients with FTD (Avants et al. 2014). These prior
studies suggest the utility of sCCA in further investigation of genotype-phenotype
relationships in ALS-FTD spectrum disease. For example, this method could be
used to evaluate multivariate relationships between patient genotypes (e.g. at
SNPs) and performance on multiple neuropsychological measures of cognition.
The aforementioned multimodal, nonparametric, and machine learning
approaches are ideally suited to the study of environmental and genetic factors
influencing heterogeneous cognitive phenotypes in the context of ALS-FTD
spectrum disease. Multimodal data collection enables deep endophenotyping of
patients including cognitive, anatomic, and genetic profiling, and allows the
evaluation of candidate environmental and genetic modifiers across multiple
datasets. Nonparametric analyses of these multimodal datasets (e.g. through
computationally-efficient permutation methods) is essential, as observational
patient data are demonstrably heterogeneous and often do not conform to
theoretical distributions of statistical normality. Additionally, sCCA, a machine-
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learning approach, can be used to integrate modalities into endophenotypes by
identifying relationships in data-driven subsets of variables across large datasets
of differing modalities, allowing for the exploration of multivariate relationships
between cognition and environmental / genetic factors. With this suitability in
mind, I combine multimodal, nonparametric, and data-driven approaches in the
series of research studies comprising the subsequent chapters of this thesis with
the goal of elucidating environmental and genetic influences on cognition in ALSFTD spectrum disease in a statistically-robust manner.
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OVERVIEW OF DISSERTATION STUDIES
In this dissertation, I present three research studies evaluating how cognition in
ALS-FTD spectrum disease is shaped by factors innate (i.e. genetic) and
external (i.e. environmental) to affected individuals. I address the following
specific questions:
1. How does lifetime cognitive engagement relate to cognition and disease
neuroanatomy in ALS-FTD spectrum disease?
2. Do common genetic variants that confer risk for ALS-FTD spectrum
disease relate to cognition and disease neuroanatomy?
3. Is there evidence of polygenic contribution via common genetic variants to
cognition and disease neuroanatomy?
I address the first research question in an initial study investigating whether
education and premorbid occupation level of patients with ALS-FTD spectrum
disease relates to heterogeneity in cognition and neurodegeneration. I use a
retrospective cohort design to study 55 patients and 90 controls with detailed
demographic information, neuropsychological evaluation, and in vivo structural
MRI from the UPenn Integrated Neurodegenerative Disease Biobank (Toledo et
al. 2014). I include patients with genetic or autopsy confirmation of Tau or TDP43 pathology in an effort to exclude dementia patients with underlying
Alzheimer’s disease pathology, and – in an effort to capture the phenotypic and
genetic heterogeneity of ALS-FTD spectrum disease – include patients ranging in
clinical phenotype and genetic mutation status. To approximate cognitive
engagement across the lifespan, I define a cumulative index of cognitive reserve
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based on years of completed education and ordinal scoring of premorbid
occupational complexity. I identify regions of gray matter atrophy from
nonparametric permutation analyses of voxel-wise gray matter probability from
T1-weighted MRI in patients relative to controls, and examine the relationship
between the cognitive reserve index and severity of gray matter atrophy in
identified regions in patients. I further examine how cognitive performance relates
to both cognitive reserve index and to gray matter regions associated with the
reserve index. Given the common frontal distribution of disease in ALS-FTD
spectrum patients, I hypothesize that cognitive reserve relates to less atrophic
frontal cortex gray matter and preserved performance on frontally-mediated
neuropsychological measures.
Next, in the second study, I investigate genetic influence on cognition and
disease anatomy in ALS-FTD spectrum disease. Specifically, I test whether
common genetic variation at rs12608932 (closest gene: UNC13A) – a locus that
previously achieved genome-wide association with both ALS and FTD - further
contributes to cognition, in vivo neurodegeneration, and post mortem pathologic
burden. I again use a retrospective cohort design of 190 patients and 113
controls from the UPenn Integrated Neurodegenerative Disease Biobank (Toledo
et al. 2014), but focus my investigation here on patients with initial onset of ALS
who also have sporadic and mutation-negative forms of disease. The 190 total
patients studied describe two cohorts; one with T1-weighted structural MRI
(N=109), a subset of whom also had neuropsychological evaluation (N=88), and
another with post mortem tissue samples graded for TDP-43 pathology (N=102).
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I additionally study 84 controls from the publicly-available Alzheimer’s Disease
Neuroimaging Initiative (ADNI) with genotyping at rs12608932 and T1-weighted
MRI. I identify regions of cortical thinning from nonparametric permutation
analyses of voxel-wise cortical thickness measurements in patients relative to
controls, and examine the relationship between rs12608932 genotype and
severity of cortical thinning in identified regions in patients and ADNI controls. I
continue to evaluate rs12608932 genotype and study its relation to cognitive
performance and to burden of TDP-43 pathology. Based on prior associations of
rs12608932 and risk for ALS and FTD, and with reduced survival in ALS, I
hypothesize that rs12608932 genotype associates with greater frontotemporal
disease in ALS as evident in reduced cortical thickness in vivo, more impaired
cognitive performance, and greater burden of TDP-43 pathology post mortem.
Finally, in the third study, I build on prior evidence for single-allelic
contribution to cognition and disease neuroanatomy from the second study to
further evaluate potential polygenic contribution using a multivariate approach. I
collaborate with investigators across institutions from the international Clinical
Research in ALS and related disorders for Therapeutic Development (CReATe)
Consortium to study an unprecedented cohort of 339 patients with longitudinal
neuropsychological evaluation and genotyping at loci of common genetic
variation that previously achieved genome-wide association with ALS or joint
association with ALS and FTD. I use sCCA, an unsupervised machine learning
approach, to identify a subset of loci that maximally contribute to cognitive
heterogeneity in this cohort and derive a data-driven polygenic risk score for
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impaired cognition from model estimates. I further evaluate this machine-learning
derived polygenic risk score relative to anatomic disease burden in independent
neuroimaging

and

autopsy

cohorts

from

the

UPenn

Integrated

Neurodegenerative Disease Biobank (Toledo et al. 2014). These include 114
ALS patients and 114 controls with T1-weighted MRI and 88 ALS patients with
post mortem tissue samples graded for TDP-43 pathology and neuronal loss. I
hypothesize that the machine learning will reveal a subset of genetic loci
associated with cognitive dysfunction profiles in ALS in a polygenic manner, and
that follow-up analyses in independent neuroimaging and autopsy cohorts
converge to characterize quantitative traits associated with polygenic risk from
identified loci.
Each study – though addressing a distinct and specific research question –
shares the common goal of elucidating factors that modify cognition and disease
anatomy in ALS-FTD spectrum disease. Critically, the environmental and genetic
factors targeted in my research can provide novel and cost-effective biomarkers
with potential for actionable use in patient prognostication and in clinical trials.

35
CHAPTER 2
Cognitive reserve in frontotemporal degeneration:
Neuroanatomic and neuropsychological evidence
Katerina Placek, Lauren Massimo, Christopher Olm, Kylie Ternes, Kimberly Firn,
Vivianna Van Deerlin, Edward B. Lee, John Q. Trojanowski, Virginia M.Y. Lee,
David Irwin, Murray Grossman, and Corey T. McMillan. Neurology, 2016,
87:1813-1819.

Abstract
In this study, we evaluate if cognitive reserve (CR) contributes to inter-individual
differences in frontal gray matter (GM) and executive impairment that underlie
heterogeneity in the disease course of confirmed frontotemporal lobar
degeneration (FTLD) pathology. Fifty-five patients with autopsy confirmation or a
pathogenic mutation consistent with underlying tau (FTLD-Tau) or TDP-43
(FTLD-TDP) pathology and 90 demographically-comparable healthy controls
were assessed with T1 MRI and neuropsychological measures (Mini

Mental

State Exam, letter fluency, forward digit span, Rey complex figure, and Boston
Naming Test). CR was indexed using a composite measure of education and
occupation. We identified reduced GM density in FTLD patients relative to
controls, ran regression analyses relating reduced GM density to CR index, and
correlated

regions

of

GM

associated

with

CR

with

performance

on

neuropsychological measures. FTLD patients exhibited reduced bilateral
frontotemporal GM relative to controls, consistent with the known anatomic
distribution of FTLD pathology. CR index was positively associated with letter
fluency and with GM density in right dorsolateral prefrontal cortex, orbitofrontal
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cortex, rostral frontal cortex, and inferior frontal gyrus. Furthermore, letter fluency
correlated positively with mean GM density in frontal GM regions associated with
CR. Our results indicate that executive control and verbal ability assessed by
letter fluency in FTLD is mediated in part by CR and frontal GM reduction. The
identification of factors influencing cognitive and anatomic heterogeneity in FTLD
suggests that CR should be considered in symptom detection, prognosis, and
treatment.
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Introduction
Frontotemporal lobar degeneration (FTLD) is a pathologic spectrum of
progressive neurodegenerative conditions affecting the frontal and temporal
lobes that are associated with executive, social, and language impairments
(Irwin, Cairns, et al. 2014). The disease course of FTLD is highly variable across
individuals, including age at onset (J. K. Johnson et al. 2005), rate of decline
(Josephs et al. 2011), and survival (Hodges et al. 2003). While some biologic
mechanisms have been proposed to account for this heterogeneity (Gallagher et
al. 2014; McMillan et al. 2015), environmental factors contributing to disease
course remain obscure.
Cognitive reserve (CR) theories suggest environmental factors including
education and occupation provide a ‘reserve’ against the clinical manifestation of
neurodegenerative disease despite significant pathological burden (Stern 2009).
Individuals

with

high

CR

may

compensate

for

dementia-associated

neurodegeneration by increasing recruitment of frontal executive resources to
improve cognitive performance and delay symptom detection (Kemppainen et al.
2008; Bosch et al. 2010). In patients with FTLD, access to frontal executive
resources is compromised early in disease course due to frontal tau or TDP-43
pathology. Prior research on CR in FTLD-spectrum disorders is largely limited to
behavioral variant frontotemporal dementia (bvFTD) patients with unconfirmed
FTLD pathology, and has largely focused on brain metabolism and other
functional measures (Perneczky et al. 2007; Borroni et al. 2009; Spreng et al.
2011). There is a thus a need for investigation of CR in FTLD-spectrum patients
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with confirmed FTLD pathology using structural measures of brain integrity.
Recent evidence from autopsy-confirmed FTLD patients suggests that
higher occupational attainment is associated with longer survival from symptom
onset (Massimo et al. 2015). From this perspective, FTLD patients with higher
occupational attainment may detect dementia symptoms earlier than lower
occupational attainment patients because of their increased frontally-mediated
work demands, therefore giving the impression that they are surviving longer.
This is in contrast with traditional CR accounts based on Alzheimer’s disease
(AD) that suggest that higher CR factors such as education and occupational
attainment are associated with shorter survival.
Critically, since AD has a neuroanatomic distribution of disease distinct
from FTLD, including less frontal lobe disease, it is reasonable to speculate that
CR may function differently in patients with FTLD. However, to our knowledge,
the anatomic and cognitive profiles associated with CR in patients with confirmed
FTLD remain unknown. Given the frontal distribution of disease in FTLD, we
hypothesized that CR would be positively associated with frontal cortex grey
matter (GM) and with frontally-mediated neuropsychological measures.

Methods
Participants.
We report 55 patients recruited from the Penn Frontotemporal Degeneration
Center at the University of Pennsylvania and clinically diagnosed by a boardcertified neurologist (M.G., D.I.) using published criteria for a clinical syndrome
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associated with FTLD pathology (Gorno-Tempini et al. 2011; Rascovsky et al.
2011; Armstrong et al. 2013; Strong et al. 2009). Inclusion criteria for this study
required a post-mortem neuropathological diagnosis or genetic screening (see
Neuropathological Diagnosis and Genetic Screening), an ante mortem T1weighted MRI scan, neuropsychological assessment, and known occupational
status and years of education. Patients’ clinical syndrome included behavioral
variant FTD (bvFTD; N=34), amyotrophic lateral sclerosis (ALS) with FTD (ALSFTD, N=7), nonfluent-agrammatic primary progressive aphasia (naPPA, N=6),
corticobasal syndrome (CBS, N=4), semantic-variant primary progressive
aphasia (svPPA, N=1) progressive supranuclear palsy (PSP, N=2), and ALS with
mild cognitive impairment (ALS-MCI, N=1). Disease duration was defined as time
of symptom onset, based on caregiver report of the earliest clinical feature, until
time of MRI acquisition. Disease duration can alternatively be calculated as
months between first diagnosis and clinical appointment and post hoc analyses
confirm that we see similar results when using this calculation (all p<0.05).
To identify regions of significant GM atrophy in FTLD (see below), we
additionally recruited 90 demographically-comparable healthy controls who selfreported a negative history for neurologic or psychiatric disease, and completed
an initial screening of Mini-Mental State Examination (MMSE)>27 (M. F. Folstein,
Folstein, and McHugh 1975). Demographic features of FTLD patients and
controls are summarized in Table 1. There were no significant differences in
age, education, gender, or CR index (see below) between controls and patients
(all p values >0.05).
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Neuropathological Diagnosis.
Neuropathologic diagnoses of FTLD-Tau and FTLD-TDP were established
according

to

consensus

criteria

(Mackenzie

et

al.

2010)

by

expert

neuropathologists (J.Q.T.; E.B.L.) using immunohistochemistry with established
monoclonal antibodies specific for pathogenic tau (mAb PHF-1) (Otvos et al.
1994) and TDP-43 (mAbs p409/410 or 171) (Neumann et al. 2009), as previously
reported (Toledo et al. 2014). Twenty patients had a primary FTLD-spectrum
neuropathologic diagnosis at autopsy including corticobasal degeneration (CBD;
N=2), PSP (N=5), Pick’s disease (N=3), referred to here collectively as FTLD-Tau
disorders, or FTLD with TDP-43 inclusions (N=10), designated here as FTLDTDP. Among those individuals with neuropathological confirmation of FTLD, five
also had genetic mutations (see below).

Genetic Screening.
DNA was extracted from peripheral blood or brain tissue following the
manufacturer’s protocols (Flexigene (Qiagen) or QuickGene DNA whole blood kit
(Autogen) for blood, and QIAsymphony DNA Mini Kit (Qiagen) for brain tissue).
Samples were genotyped for the C9ORF72 hexanucleotide-repeat using a
modified repeat-primed polymerase-chain reaction and the MAPT (exons 1, and
9-13), GRN (entire coding region), and TARDBP genes were sequenced to
identify pathogenic mutations as previously described (Toledo et al. 2014).
Sequencing data was analyzed using Mutation Surveyor software (Soft Genetics,
State College, PA). Genetic screening revealed that a total of 40 patients (five
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also with neuropathological confirmation) had a known pathogenic mutation
associated with FTLD-Tau or FTLD-TDP disorders, including mutations in MAPT
(N=7) (Hutton et al. 1998), as well as C9ORF72 expansions (N=20) (DeJesusHernandez et al. 2011; Renton et al. 2011) or mutations in the GRN (N=11)
(Baker et al. 2006), or TARDBP (N=2) (Van Deerlin et al. 2008) genes,
respectively.

Standard Protocol Approvals, Registrations, and Patient Consents.
All patients and controls participated in an informed consent procedure
approved by an Institutional Review Board convened at the University of
Pennsylvania.

Cognitive Reserve Index.
We assessed CR using a composite measure of education and occupation
similar to previous reports (Borroni et al. 2009; Premi et al. 2013). Education was
recorded in years and ranked with a score ranging from 1 to 4: (1) ≤12 years
(primary or secondary education; N=13); (2) >12 and <16 (some post-secondary
education; N=8); (3) 16 years (college education; N=11); and (4) >16 years
(graduate education; N=23). Occupation was ranked on a 1-4 point scale based
on US census categories: (1) Unskilled laborers (N=2); (2) Operative and service
workers (N=5); (3) Managers, administrators, clerical and sales (N=20); (4)
Professional and technical workers (N=28). We report a CR index as the sum of
education and occupation ranks.

42
Neuropsychological Assessment.
Neuropsychological assessment was performed within approximately two months
from date of scan (M=2.20, SE=0.53; Range=0-16). Letter fluency is a measure
of executive control and verbal ability and was assessed by the number of unique
words beginning with “F” a patient was able to generate in one minute (excluding
proper nouns and numbers) (Tombaugh, Kozak, and Rees 1999). The MMSE is
a 30-point questionnaire that evaluates global dementia severity (Crum, Anthony,
Bassett, and Folstein 1993a). Forward digit span, a measure of auditory-verbal
short-term memory, was assessed with repetition of increasingly longer
sequences until the patient erred; the maximum number of digits on a correct trial
was recorded (Wechsler 2008). Rey figure copy, a measure of visuospatial
constructional ability, required patients to copy a modified Rey complex figure
and was scored for accuracy on a 12-point scale (Libon et al. 2011). The Boston
Naming Test, a measure of confrontational word retrieval, required patients to
orally name 30 line drawings; the total number of correct responses made
without aid of a stimulus cue was recorded (Kaplan, Goodglass, and Weintraub
2001). Forward digit span was unavailable for two patients, Rey copy was
unavailable for five patients, and Boston Naming Test was unavailable for 11
patients.
In addition to reporting raw patient performance on neuropsychological
assessments, we report the proportion of patients impaired on each task relative
to published normative data of healthy controls matched to the mean age and
mean education of our patients where available (Tombaugh, Kozak, and Rees
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1999; Crum, Anthony, Bassett, and Folstein 1993a; Shirk et al. 2011); we report
patient performance on Rey copy relative to normative data based on healthy
controls recruited by the FTDC who were matched to the mean age and mean
education of our patients (N=22 (50% Female); Age, years: M=61.81, SD=4.97;
Education, years: M=15.73, SD=2.37). We defined patient impairment on each
task as performance at or greater than 1.96 standard deviations, equivalent to
p<0.05, below normative data from healthy controls.
We used linear regression to relate performance on neuropsychological
measures to CR index including age at assessment as a nuisance covariate. We
report one-tailed p values as we predicted higher CR index to relate to better
performance on neuropsychological measures.

Neuroimaging Acquisition and Preprocessing.
High-resolution T1-weighted MPRAGE structural scans were acquired using a 3T
Siemens Tim Trio scanner with an 8-channel head coil, with T=1620ms,
T=3.09ms, flip angle=15°, 192x256 matrix, and 1mm 3 voxels. T1-weighted MRI
images were then preprocessed using ANTs Cortical Thickness software
(Tustison et al. 2014). Briefly, each individual dataset was deformed into a
standard local template space in a canonical stereotactic coordinate system.
Advanced Normalization Tools (ANTs) provides a highly accurate registration
routine using symmetric and topology-preserving diffeomorphic deformations to
minimize bias toward the reference space for computing the mappings and to
capture the large deformation necessary to aggregate images in a common
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space. Then, we used N4 bias correction to minimize heterogeneity (Tustison et
al. 2010), the ANTs Atropos tool to segment images into six tissue classes
(cortex, white matter, CSF, subcortical grey structures, brainstem, and
cerebellum) using template-based priors and to generate probability maps of
each tissue. GM probability images, the sum of the cortical, subcortical, and
brainstem probability images, were then transformed into Montreal Neurological
Institute (MNI) space, smoothed using a 2 sigma full-width half-maximum
Gaussian kernel, and downsampled to 2mm isotropic voxels.

Neuroimaging Analyses.
We used randomise software implemented in FSL to perform nonparametric,
permutation-based statistical analyses (Winkler et al. 2014). Briefly, permutationbased statistical testing is robust to concerns regarding multiple comparisons
since, rather than a traditional assessment of two sample distributions, this
method assesses a true assignment of factors (e.g., group, CR index) to GM
relative to many (e.g., 10,000) random assignments. We adopt a priori statistical
thresholds consistent with similar prior reports that include FWE–correction for
group comparison of GM (Ash et al. 2014), and to minimize Type II error (not
observing a true regression result) we employ uncorrected p-values for GM
regressions.
Analysis 1. First, we evaluated regions of reduced GM in FTLD patients
relative to controls using a nonparametric group comparison analysis. For this
analysis we constrained analysis using an explicit mask that was restricted to
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include only high probability GM (>0.5). We report clusters that survive a
p<0.001 (FWE) threshold and cluster extent of >50 adjacent voxels relative to
10,000 random permutations.
Analysis 2. Second, we conducted two regression analyses to test
whether CR index is associated with GM density in FTLD patients (Analysis 2a)
and in healthy controls (Analysis 2b), and restricted both analyses to a mask
defined by regions of reduced GM in patients relative to controls from Analysis 1.
This mask was used so that we could focus our interpretation of CR in the
context of GM regions affected by FTLD.

Otherwise, it would be difficult to

interpret how regions of GM that are not different from controls contribute to
cognitive function in domains impaired in FTLD syndromes. Refer to Table 4 for
whole-brain analyses that do not include an explicit mask of reduced GM density.
We report clusters that survive a p<0.05 (uncorrected) threshold and
cluster extent threshold of >50 adjacent voxels relative to 10,000 random
permutations. Analysis 2a (FTLD patients) included disease duration and age at
MRI as nuisance covariates, and Analysis 2b (healthy controls) included age at
MRI as a nuisance covariate in an effort to control for factors associated with
individual differences in GM but not specifically associated with CR.
Analysis 3. In a third and final set of analyses, we used Pearson
correlations to examine the relationship between regions associated with CR in
FTLD patients and performance on neuropsychological measures. For each
patient, we extracted the mean GM density in each region identified as
associated with CR index from Analysis 2a. We then correlated mean GM
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density with performance on each neuropsychological test and report Bonferronicorrected p-values.

Results
Neuropsychological assessment.
Patients demonstrated most impairment on letter fluency (70.91% impaired)
consistent with compromised frontal resources relative to other domains
including attention on forward digit span (18.87% impaired), visuospatial function
on Rey copy (56% impaired), non-specific global cognitive impairment on MMSE
(58.18% impaired), and language deficits on the Boston Naming Test (36.36%
impaired) (Table 1). Regression analyses indicated that higher CR index was
associated with better performance on letter fluency (95% CI=-0.015, 1.38;
t=1.96, p=0.028), but not MMSE, forward digit span, Rey copy, or Boston Naming
Test (all p>0.05).

Neuroimaging.
FTLD patients had reduced GM density relative to controls throughout bilateral
frontal and temporal lobes, consistent with the known pattern of GM disease
associated with FTLD pathology (Analysis 1, Table 2, Figure 1A).
By restricting analysis to regions where patients exhibited reduced GM
density relative to controls, we next found that CR index in patients was positively
associated with GM density in right frontal cortex, including rostral, orbital,
inferior, and dorsolateral prefrontal regions (Analysis 2a, Table 2, Figure 1B).
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Thus, a patient with a higher CR index exhibited higher frontal GM density in
these diseased regions in comparison to a patient with a lower CR index. We
found no inverse association between CR index and GM density in any region of
reduced GM density relative to controls (not shown).
To examine the specificity of the relationship between CR index and GM
density in FTLD, we performed a comparable analysis in controls restricted to the
same GM regions as the regression analysis in patients. We found that CR index
in controls was positively associated with GM density in the left inferior frontal
gyrus only (Analysis 2b, Table 2, Figure 1C).
In patients, frontal GM density related to higher CR index was also
positively associated with performance on letter fluency (p<0.05), but not MMSE,
forward digit span, Rey copy, or Boston Naming Test (all p>0.05) (Analysis 3,
Table 3, Figure 2). This finding was anatomically specific such that regions of
frontal GM density not related to CR were not associated with performance on
letter fluency, or MMSE, forward digit span, Rey copy, or the Boston Naming
Test (all p>0.05) (not shown).

Post hoc Analyses.
While our primary analyses use a CR index, we performed post hoc analyses to
evaluate whether education and occupational attainment alone are similarly
related to neuroimaging results (Table 5, Figure 3). These post hoc analyses
largely converge with our CR index analyses: when considered separately,
educational and occupational category are positively associated with GM density
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in right frontal cortical regions similar to results obtained when using the CR
index. Educational category also positively relates to GM density in the right
caudate and left premotor cortex, and occupational category also positively
relates to regions in bilateral temporal cortices and in the left frontal cortex.
To evaluate whether right frontal GM density associated with CR is
partially driven by sources of heterogeneity in our cohort we also performed post
hoc logistic regression analyses evaluating neuropathological, genetic, and
clinical subgroups. First, we observed that mean GM density in right rostral,
orbital, inferior, and dorsolateral prefrontal regions were not significant predictors
of tau versus TDP-43 pathological subgroups (all factors p>0.10). Second, we
observed that each of these four GM regions also were not significant predictors
of genetic mutation or sporadic forms of disease (all factors p>0.10). Last, we
evaluated whether the four GM regions associated with CR were significant
predictors of bvFTD clinical phenotype versus other phenotypes, since bvFTD is
the predominant phenotype in our cohort. This analysis revealed that one region,
right dorsolateral prefrontal cortex, (p=0.048) was more reduced in bvFTD
relative to other phenotypes, however all remaining regions did not differ (all
p>0.05). Together, these findings are suggestive that these sources of
heterogeneity are not likely confounding our observed findings related to CR in
FTLD.

Discussion
Our results suggest that CR contributes to inter-individual differences in reduced
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frontal GM density and executive impairment that underlie heterogeneity in the
disease course of FTLD. In an analysis restricted to frontal and temporal lobe
regions of reduced GM density relative to controls, patients with higher CR
exhibited higher GM density in right frontal cortical regions compared to patients
with lower CR. Moreover, we demonstrate that regions related to CR in FTLD
appear to be specific: CR in control participants was only related to higher GM
density in the left IFG. In FTLD patients, higher frontal GM density in right frontal
cortical regions was associated with superior performance on letter fluency, a
neuropsychological measure of executive control and verbal ability indicative of
frontal lobe integrity. These findings are consistent with a reserve model linking
preserved frontal anatomic integrity and superior strategic processing to the
prolonged survival of patients with FTLD who have higher education and
occupational attainment (Massimo et al. 2015).
Our findings are consistent with other evidence suggesting that CR is an
environmental factor influencing the spectrum of disease in FTLD. Prior
neuroimaging studies of behavioral bvFTD patients with unconfirmed FTLD
pathology indicate CR may counteract the onset of dementia (Borroni et al. 2009;
Perneczky et al. 2007; Spreng et al. 2011), while a recent survival analysis in
patients with autopsy-confirmed FTLD pathology by our group indicates that
higher occupational attainment is associated with prolonged survival from
symptom onset (Massimo et al. 2015). These studies suggest that, despite the
commonality of frontotemporal-predominant neurodegeneration, patients with
FTLD appear to exhibit heterogeneous disease course that is determined in part

50
by environmental factors related to CR. It is imperative to identify and understand
potential environmental contributors to the rate of decline in FTLD, as these may
serve as prognostic markers and eventual therapeutic targets.
Our analysis of CR in control participants demonstrates specificity of
higher GM density in right frontal cortex associated with CR in FTLD patients.
Several other studies have investigated CR in healthy controls, demonstrating a
positive relationship between CR and structural brain integrity. For example, one
study demonstrates that in healthy older controls, higher years of education are
positively associated with GM volume in the superior temporal gyrus, insula, and
anterior cingulate cortex (Arenaza-Urquijo et al. 2013). While we similarly found a
positive association between CR index and GM density in the left IFG in our
healthy control group, this region did not overlap with any region of higher GM
density associated with higher CR index in our patient group. We interpret this to
suggest that our findings of higher GM density associated with higher CR in the
right rostral and orbital frontal cortex, dorsolateral prefrontal cortex, and inferior
frontal gyrus are specific to FTLD patients. Future work is necessary to evaluate
the potential role of left IFG in CR in healthy controls, but limited
neuropsychological data in the current control cohort precludes our ability to
evaluate the behavioral consequences of this association.
To our knowledge, no prior studies have examined the association
between CR and heterogeneity in neuroanatomical structure and cognitive
function in patients with a clinical FTLD syndrome due to confirmed FTLD-Tau or
FTLD-TDP pathology. Some studies report that patients with clinically diagnosed

51
FTD who have higher education and occupation exhibit evidence of greater
frontal disease as measured by regional cerebral glucose utilization and regional
cerebral blood flow (Borroni et al. 2009; Perneczky et al. 2007; Spreng et al.
2011). These studies have been interpreted to suggest that CR confers
compensatory benefit such that individuals with FTD who have higher CR can
better withstand accumulating frontotemporal pathology than individuals with
lower CR, and therefore delay symptom presentation. This resembles findings
reported in Alzheimer’s disease (Kemppainen et al. 2008; Bosch et al. 2010).
However, differences in patient population and study design necessitate cautious
interpretation of these results. For example, as many as 16.7% of patients with
FTD-related syndromes have AD neuropathology (Forman et al. 2006).
Furthermore, the relationship between higher CR and greater frontotemporal
pathology is difficult to interpret in this work in the absence of neuropsychological
data. For example, it is unclear if for the same severity of frontotemporal
pathology, FTD patients with higher CR demonstrate better cognitive or
behavioral function than FTD patients with lower CR. Future research is needed
to provide a more detailed assessment of how structural GM, functional imaging,
and neuropsychological measures interact in the context of CR.
Several mechanisms may underlie the association between higher CR
index and higher right frontal cortex GM density and superior letter fluency in
FTLD patients. One possible mechanism is inter-individual differences in genetic
predisposition. For example, genetic studies in healthy twins suggest that there is
a genetic contribution to normal variation in human cognitive function and brain
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morphology, including frontal cortex GM volume (Pol et al. 2006). Another
possibility is that higher frontal GM and superior cognitive function in FTLD
patients with higher CR may be a function of earlier stages of disease. For
example, patients with higher education and occupational attainment who are
more dependent on frontally-mediated executive functions may be more sensitive
to the emergence of cognitive difficulty, leading to clinical symptom detection at
an earlier stage of disease. Either of these proposed mechanisms could result in
patients with higher CR exhibiting relatively higher frontal GM and superior letter
fluency compared to patients with lower CR. Longitudinal structural and
functional neuroimaging and neuropsychological assessment in controls and
FTLD patients are necessary to evaluate individual differences in rates of
disease progression underlying heterogeneity in FTLD disease course related to
education and occupation as proxies of CR.
Our findings contribute to a growing body of evidence for factors thought
to influence heterogeneity in FTLD disease course, and suggest the
consideration of both biological and environmental factors. Others suggest that
risk alleles in single nucleotide polymorphisms, including rs1768208 in myelin
oligodendrocyte basic protein (MOBP) gene and rs1990622 in the TMEM106B
gene (McMillan et al. 2014; Gallagher et al. 2014), are associated with greater
pathology and earlier age of onset and death in FTLD. Moreover, recent
evidence

indicates

that

epigenetic

factors

like

C9ORF72

promoter

hypermethylation are associated with reduced neuronal loss and reduced GM
atrophy in frontal cortex (McMillan et al. 2015). While genetic factors may
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contribute to heterogeneity in the disease course of FTLD, our exploratory
analyses suggest that genetic status is not a confounder of the current
observations.

Future

research

should

investigate

interactions

between

environmental factors, like CR, and biological factors, like genetics and
epigenetics, on clinical heterogeneity in FTLD.
Several potential caveats should be considered in the current study. We
assessed CR using a composite index of education and occupation. While our
observation that education and occupation independently also relate to right
frontal GM, we also observed that each of these measures has some distinct
frontal associations with GM. Future work evaluating the difference between
these measures would be valuable. Moreover, future research should also
consider other environmental factors implicated in CR such as midlife leisure
activities (Scarmeas et al. 2001). Our patient cohort self-reported predominant
white race and most received a college education; thus, more racially and
educationally-diverse samples are needed in future studies of CR in patients with
FTLD. Another caveat to consider is that the current study cohort included
several different clinical phenotypes with a majority of our sample being
comprised of bvFTD and the remaining consisting of primary progressive
aphasias and movement disorders (e.g., CBS, PSP). While future research is
necessary to stratify by clinical phenotype, our post hoc analyses suggested that
only one GM region, right dorsolateral prefrontal cortex, was related to bvFTD.
Importantly, regions implicated in CR that are most likely to be shared across
clinical phenotypes, such as right inferior frontal gyrus, did not show differences
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in GM density. Other sources of heterogeneity in our patient cohort including
presence/absence of a genetic mutation and FTLD-Tau/FTLD-TDP pathology
also did not appear to contribute to GM differences in regions related to CR,
though future studies must address these distinct groups.
With these caveats in mind, we conclude that CR is an environmental
factor contributing to heterogeneity in executive control and verbal ability of
patients with known FTLD pathology mediated by neuroanatomic structure.
These findings stimulate investigation into additional environmental contributors
to disease course, and suggest their importance in prognostic considerations and
treatment trials in patients with FTLD.
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Table 1. Mean (standard deviation) of frontotemporal lobar degeneration patient
and control demographics and neuropsychological evaluation.
N (F)
Age, years
Education, years
Education, N per rank:
1
2
3
4
Occupation, N per rank
1
2
3
4
CR Index
MMSE (max=30)
Proportion impaired (%)
Letter Fluency (words/min)
Proportion impaired (%)
Forward Digit Span (# repeated)
Proportion impaired (%)
Rey copy (max=12)
Proportion impaired (%)
Boston Naming Test (max=30)
Proportion impaired (%)

FTLD
55 (20)
61.2 (8.07)
16.1 (3.11)

Controls
90 (40)
60.3 (8.65)
15.4 (2.49)

13
8
11
23

14
28
27
21

2
5
20
28
6.14(1.79)
23.36 (6.85)
32/55 (58.18)
6.04 (4.72)
39/55 (70.91)
5.17 (1.71)
10/53 (18.87)
9.48 (3.56)
28/50 (56)
20.5 (8.08)
16/44 (36.36)

13
30
47
5.98 (1.55)
-

Abbreviation: MMSE=Mini-Mental State Examination

-
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Table 2. Results of a group comparison analysis showing regions of reduced
gray matter (GM) density in frontotemporal lobar degeneration (FTLD) patients
relative to healthy controls (Analysis 1), and results of regression analyses in
patients (Analysis 2a) and controls (Analysis 2b) showing a positive relationship
between GM density and cognitive reserve (CR) in regions from Analysis 1.
Neuroanatomic region (BA)

L/R

p
value

Voxels

Analysis 1. Reduced GM density in FTLD relative to
controls:
Occipital Temporal Cortex (37)

MNI
Coordinates
x
y
z

R

36

0

-46

0.001

8250

Inferior Temporal Cortex (20)

L

-34

0

-46

0.001

6966

Orbital Frontal Cortex (11/25)

L

-8

24

-26

0.001

838

Thalamus/Hypothalamus

R

2

-10

-14

0.001

586

R

32

-10

-24

0.001

180

Parietal Cortex (40)

L

-62

-28

20

0.001

142

Hippocampus

L

-22

-10

-26

0.001

119

Superior Temporal Cortex (22)

R

66

-30

18

0.001

75

Parietal Cortex (40)

R

62

-28

40

0.001

72

Angular Gyrus (39)

R

64

-44

26

0.001
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Hippocampus

Analysis 2a. Higher GM density associated with higher CR in FTLD:
Rostral Frontal Cortex (10)

R

32

50

20

0.001

133

Orbital Frontal Cortex (47)

R

50

28

-4

0.003

123

Inferior Frontal Gyrus (44/45)

R

52

12

22

0.01

64

Dorsolateral Prefrontal Cortex (8/9)

R

44

6

40

0.005

59

6

0.003

60

Analysis 2b. Higher GM density associated with higher CR in controls:
Inferior Frontal Gyrus (44/45)

L

-42

18

Abbreviations: BA = Brodmann area; L/R = Left/Right; MNI = Montreal
Neurological Institute
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Table 3. In FTLD patients, mean GM density in regions positively associated with
CR from Analysis 2a are also positively correlated with performance on letter
fluency, but not on MMSE, forward digit span, Rey copy, or the Boston Naming
Test (Analysis 3).

R Rostral
Frontal
Cortex
R Orbital
Frontal
Cortex
R Inferior
Frontal
Gyrus
R
Dorsolateral
Prefrontal
Cortex

Letter Fluency

MMSE

N=55

N=55

Forward Digit
Span
N=53

Rey Copy
N=50

Boston
Naming
Test
N=44

*0.45, p=0.02

0.31, p=0.4

0.082, p>0.99

0.16, p>0.99

0.12, p>0.99

0.39, p=0.06

0.29, p=0.58

0.098, p>0.99

0.21, p>0.99

0.21, p>0.99

**0.51, p<0.001

0.28, p=0.8

0.14, p>0.99

0.39, p=0.1

0.39, p>0.99

*0.40, p=0.04

0.23, p > 0.99

0.24, p>0.99

0.34, p=0.32

0.34, p>0.99

Note. Bonferroni corrected *p<0.05; **p<0.001
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Table 4. Results of two whole-brain regression analyses examining CR index
relative to whole-brain GM density in FTLD patients and in controls. We report
clusters that survive a p<0.05 (uncorrected) threshold and cluster extent
threshold of >50 adjacent voxels relative to 10,000 random permutations.
Regression analysis in patients included disease duration and age at MRI as
nuisance covariates, and regression analysis in healthy controls included age at
MRI as a nuisance covariate.
Neuroanatomic region (BA)

L
/
R

Higher GM density associated with higher CR in FTLD:

MNI Coordinates

p
value

Voxels

x

y

z

Dorsolateral Prefrontal Cortex (9)

R

34

36

38

0.001

479

Rostral Frontal Cortex (10)

R

36

42

10

0.001

455

Visual Association Cortex (18)

L

-30

-90

-10

0.001

339

Fusiform Gyrus (37)

R

60

-40

-22

0.001

296

Visual Association Cortex (19)

R

36

-88

-14

0.001

234

Orbital Frontal Cortex (47)

R

50

28

-4

0.003

195

Premotor Cortex (6)

L

-26

0

64

0.001

115

Premotor Cortex (6)

R

58

2

44

0.003

110

Supramarginal Gyrus (40)

L

-54

-40

40

0.001

106

Premotor Cortex (6)

L

-10

-106

2

0.001

90

Premotor Cortex (6)

R

28

6

56

0.001

64

Supramarginal Gyrus (40)

R

56

-40

36

0.004

61

Middle Temporal Gyrus (21)

L

-62

-24

-16

0.002

60

Cerebellum

L

-34

-86

26

0.002

59

Rostral Frontal Cortex (10)

L

-44

46

22

0.004

59

Middle Temporal Gyrus (21)

L

-64

-38

-8

0.003

54

Supramarginal Gyrus (40)

R

50

-48

44

0.004

52

Higher GM density associated with higher CR in
controls:
Posterior Cingulate Cortex (31)

L

-8

-38

-44

0.001

392

Anterior Temporal Cortex (38)

R

46

22

-30

0.001

183

Inferior Frontal Gyrus (45)

L

-56

22

12

0.001

117

Visual Association Cortex (18)

L

-4

-96

-14

0.001

107

Visual Association Cortex (18)

L

-4

-96

14

0.004

74

Primary Visual Cortex (17)

R

8

-82

8

0.005

61

Orbital Frontal Cortex (11)

R

12

34

-26

0.003

56

Primary Sensory Cortex (1)

R

64

-18

34

0.001

52

Abbreviations: BA = Brodmann area; L/R = Left/Right; MNI = Montreal
Neurological Institute
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Table 5. Results of two regression analyses showing a positive relationship
between GM density and education and occupation in regions from Analysis 1 in
FTLD patients. We report clusters that survive a p<0.05 (uncorrected) threshold
and cluster extent threshold of >50 adjacent voxels relative to 10,000 random
permutations. Regression analysis in patients included disease duration and age
at MRI as nuisance covariates.
Neuroanatomic region (BA)

L/R

Higher GM density associated with higher education in
FTLD:
Inferior Frontal Gyrus (44)
R

MNI
Coordinates
x
y
z

p
value

Voxels

58

10

22

0.002

316

Rostral Frontal Cortex (10)

R

42

44

10

0.001

194

Orbital Frontal Cortex (47)

R

50

34

-6

0.002

146

Caudate (48)

R

12

8

10

0.005

119

Premotor Cortex (6)

L

-50

0

50

0.006

66

Higher GM density associated with higher
occupation in FTLD:
Orbital Frontal Cortex (47)

R

44

30

-14

0.001

1310

Orbital Frontal Cortex (47)

L

-40

30

-16

0.001

508

Orbital Frontal Cortex (11)

R

8

36

-24

0.001

473

Middle Temporal Gyrus (21)

R

58

-8

-16

0.002

448

Inferior Frontal Gyrus (44)

R

58

10

20

0.001

436

Rostral Frontal Cortex (10)

L

-36

56

6

0.002

262

Anterior Temporal Cortex (38)

R

30

8

-40

0.004

135

Anterior Temporal Cortex (38)

L

-32

18

-36

0.007

87

Inferior Frontal Gyrus (44)

L

-62

-18

-22

0.003

74

Dorsolateral Prefrontal Cortex (46)

L

-40

30

22

0.005

65

Orbital Frontal Cortex (11)

L

-8

40

-24

0.007

52

Abbreviations: BA = Brodmann area; L/R = Left/Right; MNI = Montreal
Neurological Institute
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Figure 1. (Analysis 1) Results of a nonparametric t-test showing regions of
reduced grey matter (GM) density in Frontotemporal Lobar Degeneration patients
(N=55) relative to demographically-comparable controls (N=90). (Analysis 2a)
Results of a regression analysis in FTLD patients (N=55) restricted to regions of
reduced GM density from Analysis 1 (white regions) demonstrating that GM
density in the right dorsolateral prefrontal cortex, rostral frontal cortex, orbital
frontal cortex, and inferior frontal gyrus is positively associated with Cognitive
Reserve (CR) index. (Analysis 2b) Results of a regression analysis in healthy
controls (N=90) demonstrating that GM density in the left inferior frontal gyrus is
positively associated with CR index. Color bar represents 1—p-value with yellow
representing highest significance.
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Figure 2. Mean GM density in the right rostral frontal cortex, inferior frontal
gyrus, orbital frontal cortex, and dorsolateral prefrontal cortex positively
associated with CR from Analysis 2a are also positively associated with
performance on letter fluency in FTLD patients (N=55).
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Figure 3. Results of a regression analysis in FTLD patients (N=55) restricted to
regions of reduced GM density from Analysis 1 (pictured in white) demonstrating
that when considered separately, educational category (A) and occupational
category (B) each are significantly positively associated with right frontal cortex
GM density, largely converging with our results using Cognitive Reserve (CR)
index as a combined metric of educational and occupational category (Post hoc
Analyses). Color bar represents 1—p-value with yellow representing highest
significance.
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CHAPTER 3
UNC13A polymorphism contributes to frontotemporal disease in sporadic
amyotrophic lateral sclerosis
Katerina Placek, G. Michael Baer, Lauren Elman, Leo McCluskey, Laura
Hennessy, Pilar M. Ferraro, Edward B. Lee, Virginia M.Y. Lee, John Q.
Trojanowski, Vivianna M. Van Deerlin, Murray Grossman, David Irwin, and Corey
T. McMillan. Neurobiology of Aging, 2019, 73:190-199.

Abstract
The majority (90-95%) of amyotrophic lateral sclerosis (ALS) is sporadic, and
~50% of patients develop symptoms of FTD associated with shorter survival. The
genetic polymorphism rs12608932 in UNC13A confers increased risk of sporadic
ALS and sporadic frontotemporal degeneration (FTD), and modifies survival in
ALS. Here, we evaluate whether rs12608932 is also associated with
frontotemporal disease in sporadic ALS. We identified reduced cortical thickness
in sporadic ALS with T1-MRI (N=109) relative to controls (N=113), and observed
that minor allele (C) carriers exhibited greater reduction of cortical thickness in
dorsal prefrontal, ventromedial prefrontal, anterior temporal, and middle temporal
cortices and worse performance on a frontal-lobe mediated cognitive test
(reverse digit span). Association between rs12608932 and cortical thickness was
not observed in an independent control cohort from the Alzheimer’s Disease
Neuroimaging Initiative (N=84). In sporadic ALS with autopsy data (N=102),
minor allele homozygotes exhibited greater burden of pTDP-43 pathology in the
middle frontal, middle temporal, and motor cortices. Our findings demonstrate
converging evidence that rs12608932 may modify frontotemporal disease in
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sporadic ALS, and suggest that rs12608932 may function as a prognostic
indicator and could be used to define patient endophenotypes in clinical trials.

Introduction
Amyotrophic lateral sclerosis (ALS) is a multi-system disorder primarily
characterized by progressive degeneration of the upper and lower motor neurons
(UMN, LMN) and affected individuals typically survive 2-5 years from symptom
onset (Chiò et al. 2009). An estimated ~50% of individuals with ALS also develop
impairments in at least one cognitive domain including executive function, social
behavior, or language indicative of extramotor neurodegeneration in the frontal
and temporal lobes, and about 10% of these individuals develop multi-domain
impairments consistent with frank frontotemporal degeneration (FTD) (Montuschi
et al. 2015; Ringholz et al. 2005). While ALS and FTD commonly feature tar
DNA-binding protein-43kda (TDP-43) pathology (Neumann et al. 2006) and can
both be caused by pathogenic C9ORF72 repeat expansions (Renton et al. 2011;
DeJesus-Hernandez et al. 2011), the mechanisms influencing the risk of
progression from ALS to develop cognitive impairment and FTD have been
under-evaluated. The presence of FTD is consistently associated with shorter
survival in ALS patients (Govaarts et al. 2016; Elamin, Phukan, Bede, Jordan,
Byrne, Pender, and Hardiman 2011b), and therefore it is critical to identify risk
factors for frontotemporal disease in ALS.
The vast majority of ALS is considered “sporadic”, with only a small
proportion of approximately 5-10% of ALS patients featuring a familial history or
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autosomal dominant source of disease (e.g. C9ORF72 expansions) (Taylor,
Brown, and Cleveland 2016). Therefore, it is important to consider sources of
common genetic variation that may influence risk of disease – including FTD - in
ALS. Case-control genome-wide association studies (GWAS) have identified
several single nucleotide polymorphisms (SNPs) associated with increased odds
of having ALS (van Rheenen et al. 2016) or FTD (Van Deerlin et al. 2010). More
recently, two loci, including rs3849942 in the C9ORF72 gene and rs4239633 in
the UNC13A gene demonstrate shared genetic overlap between ALS and FTD
(Karch et al. 2018). The observed rs3849942 SNP is a marker of the C9ORF72
expansion haplotype (Jones et al. 2013) with no additional genetic influence
reported. However, loci in UNC13A including rs12608932, that is in high linkage
disequilibrium (LD) with rs4239633 (D’=0.83), are associated with increased risk
of sporadic ALS (van Es et al. 2009) and sporadic FTD with underlying TDP-43
pathology (Diekstra et al. 2014). Clinical studies have further suggested that the
minor allele (C) of rs12608932 (MAF=0.43) is associated with shorter survival in
sporadic ALS, which has been demonstrated in multiple populations and under
both additive and recessive minor allele models (Diekstra et al. 2012; VidalTaboada et al. 2015; Chiò et al. 2013).
In this report we perform a multimodal evaluation of rs12608932 to further
investigate evidence for shared risk between ALS and FTD. Specifically, we test
the hypothesis that the disease-associated allele (C) in rs12608932 is associated
with frontotemporal cortical disease in sporadic ALS, including reduced cortical
thickness, impaired cognitive performance, and increased vulnerability to TDP-43
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pathology.
Methods
We evaluated 190 sporadic ALS cases distributed across a neuroimaging,
neuropathological, and/or neuropsychological cohort, described in detail below.

Neuroimaging cohort.
We retrospectively evaluated 109 sporadic ALS patients recruited for research
between 2004 and 2017 from the Penn Comprehensive ALS Clinic and Penn
Frontotemporal Degeneration Center at the University of Pennsylvania Perelman
School of Medicine. All patients were diagnosed with ALS by a board-certified
neurologist (L.E., L.M., M.G., D.I) using the revised El Escorial criteria (Brooks et
al. 2000), including possible, probable, and definite ALS. All patients were also
assessed for frontotemporal dysfunction using established criteria (Strong et al.
2009) and those patients enrolled in research prior to 2009 were retrospectively
evaluated through a chart review; in total 26 patients were diagnosed with ALSFTD and 11 patients were diagnosed with ALS-cognitive impairment (ALSci).
To identify regions of significant cortical thinning in ALS, we recruited 113
demographically-comparable healthy controls who self-reported a negative
history for neurologic or psychiatric disease and scored >27 on the MMSE. There
were no statistically significant differences in age, education, or sex between
controls and ALS (all p values > .05). We assessed participant race and ethnicity
via self-report. While population diversity is known to influence allele frequency
across individuals, rs12608932 has a relatively equal minor allele frequency
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across populations (e.g., European 0.35, Africans 0.33, American 0.30) and posthoc analyses limited to the majority race and ethnicity of our patient population
(e.g. white non-Latino) remain significant or approach significance. Demographic
features of ALS and controls are summarized in Table 6.
All participants participated in an informed consent procedure approved by
an Institutional Review Board convened at the University of Pennsylvania.

Autopsy cohort.
We evaluated neuropathological data from 102 sporadic ALS autopsy cases who
were diagnosed by a board-certified neuropathologist (JQT, EBL) with ALS due
to TDP-43 pathology using immunohistochemistry (Lippa et al. 2009; Neumann
et al. 2006) and published criteria (Mackenzie et al. 2011). This cohort included
21 patients from the ALS neuroimaging cohort. Autopsy cases were identified
from the Integrated Neurodegenerative Disease Database (Toledo et al. 2014)
after excluding cases with a family history of neurodegenerative disease or a
known genetic mutation associated with ALS (see Genetic Screening). Within
this autopsy cohort we rated the extent of phosphorylated TDP-43 (pTDP-43)
intraneuronal inclusions (dots, wisps, skeins) for each sampled region on a semiquantitative ordinal scale: 0 = none/rare, 1 = mild, 2 = moderate, 3 =
severe/numerous (Toledo et al. 2014). All neuropathological ratings were
performed by an expert neuropathologist (JQT, EBL) blinded to genotype.
Demographic features of ALS autopsy cases are summarized in Table 7.
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Alzheimer’s disease neuroimaging initiative (ADNI) cohort.
To evaluate the disease specificity of any observed neuroanatomic and genetic
associations we additionally performed cortical thickness analyses in 84 amyloidnegative (florbetapir SUVR <1.11) (Landau et al. 2012), cognitively-normal
healthy controls from the publicly-available Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database.

Genetic screening.
DNA was extracted from peripheral blood or frozen brain tissue following the
manufacturer’s protocols (Flexigene (Qiagen) or QuickGene DNA whole blood kit
(Autogen) for blood, and QIAsymphony DNA Mini Kit (Qiagen) for brain tissue).
All patients were screened for C9ORF72 hexanucleotide repeat expansions
using a modified repeat-primed polymerase-chain reaction (PCR) as previously
described (Suh et al. 2015), and we excluded any patient with >=30
hexanucleotide repeats. Of the remaining individuals, we evaluated

family

history using a three-generation pedigree history as previously reported (Wood et
al. 2013). For cases with a family history of the same disease we sequenced 45
genes previously associated with neurodegenerative disease (Toledo et al.
2014), including four genes known to be associated with ALS (e.g. SOD1 (D. R.
Rosen 1993), TARDBP (Kabashi et al. 2008), FUS (Kwiatkowski et al. 2009;
Vance et al. 2009), and VCP (J. O. Johnson et al. 2010)). Sequencing was
performed using a custom-targeted next-generation sequencing panel (MiND-
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Seq) (Toledo et al. 2014), and analyzed using Mutation Surveyor software (Soft
Genetics, State College, PA). We excluded any individuals identified as having a
pathogenic mutation.

SNP genotyping.
All neuroimaging and neuropathology cases were genotyped using peripheral or
brain DNA, extracted as above, for rs12608932 using a custom-designed Pan
Neurodegenerative Disease-oriented Risk Allele (PANDoRA) panel designed to
genotype 92 common and risk allele variants identified in association and other
studies

as

modifying

risk

of

disease

or

a

phenotype

for

several

neurodegenerative diseases, including ALS as well as FTD, Parkinson’s disease,
and Alzheimer’s disease (Toledo et al. 2014). While our analyses focus on a
single genotype, rs12608932, this approach provides a cost-effective manner to
genotyping that can be used for future comparative studies as previously
reported by our center (McMillan et al. 2018; McMillan et al. 2014). Briefly, the 92
SNP Type assays were designed by D3 Assay Design tool (Fluidigm). Allelespecific PCR was performed using the 96.96 Dynamic Array integrated fluidic
circuits (Fluidigm) and genotyping was carried out using the BioMark HD system
(Fluidigm) according to the manufacturer’s protocol. The genotype call data was
collected and analyzed using BioMark Genotyping Analysis software.
All ADNI healthy control data was genotyped using the Illumina 660K, as
previously described (Del-Aguila et al. 2018). As part of routine quality control
steps, single-nucleotide polymorphisms (SNPs) with minor allele frequency < 1%,

call rates < 98%, Hardy–Weinberg equilibrium p-values

>10-6
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and individuals with

> 2% missing genotypes were removed before imputation. The dataset was
imputed, separately, using SHAPEIT/IMPUTE2 with the 1000 Genomes Project
as the reference panel. All genotypes with dosage levels <0.9 for all three
possible genotypes or with information scores <0.3 were excluded. Variants out
of Hardy Weinberg Equilibrium (HWE) (p<1x10-6) or with a genotyping rate below
95% were also omitted from the analyses. Population structure was inferred by
principal component (PC) analysis using PLINK v.1.9. PLINK v1.9 was also used
to find duplicate and related individuals who were eliminated from the analysis.

Clinical evaluations.
Detailed clinical evaluations were available for a subset of 88 (79%) sporadic
ALS patients in the neuroimaging cohort. These patients were clinically
assessed within approximately two months of neuroimaging acquisition date (M
=1.62, SD = 2.63) for motor function using the Revised ALS Functional Rating
Scale (ALSFRS-R) (Cedarbaum, Stambler, Malta, Fuller, Hilt, Thurmond, and
Nakanishi 1999a) and cognitive function using the Forward and Reverse Digit
Span, the Visual-Verbal Test (VVT), letter fluency, and the Mini-Mental State
Exam (MMSE). Forward digit span, a measure of auditory-verbal short-term
memory, and reverse digit span, a measure of auditory-verbal working memory,
were assessed in an untimed manner with repetition of increasingly longer
sequences until the patient erred; the maximum number of digits on a correct trial
was recorded (Wechsler 1945). Our group has previously demonstrated that the

71
VVT is a brief, untimed measure of cognitive flexibility with minimal motor
demands appropriate for use in an ALS patient population (Evans et al. 2015).
Participants first identify a feature shared by three of four simple geometric
designs, and are next challenged to identify a different feature shared by another
combination of three of the four same geometric designs; a discrepancy between
the number correct on the first and second identifications of 10 trials is
considered a sign of reduced mental flexibility. Letter fluency is a measure of
executive control and verbal ability (Abrahams et al. 2000), and was assessed by
the number of unique words beginning with “F” a patient was able to generate in
one minute (excluding proper nouns and numbers); patients did not complete
letter fluency if bulbar upper or lower motor symptoms were present upon exam.
The MMSE is a 30-point questionnaire that evaluates global dementia severity
(Crum, Anthony, Bassett, and Folstein 1993b); we calculated the percentage
correct on MMSE as some patients were not able to complete the entire test due
to motor disability.
In addition to reporting raw patient performance on neuropsychological
assessments, we report the percent of patients impaired on each task relative to
published normative data of healthy controls matched to the mean age and mean
education of our patients where available (Tombaugh, Kozak, and Rees 1999;
Weintraub et al. 2009). We report patient performance on the Visual Verbal Test
relative to normative data based on healthy controls recruited by the Penn
Frontotemporal Degeneration Center who were matched to the mean age and
mean education of our patients (N=31 (17 Female); Age, years: M=60.58,
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SD=12.80; Education, years: M=15.29, SD=2.52). We defined patient impairment
on each task as performance at or greater than 1.96 standard deviations,
equivalent to p<0.05, below normative data from healthy controls.

Neuroimaging acquisition & processing.
High-resolution T1-weighted MPRAGE structural scans were acquired for
neuroimaging participants using a 3T Siemens Tim Trio scanner with an 8channel head coil, with T=1620ms, T=3.09ms, flip angle=15°, 192x256 matrix,
and 1mm3 voxels. T1-weighted MRI images were then preprocessed using ANTs
Cortical Thickness software (Tustison et al. 2014). Each individual dataset was
deformed into a standard local template space in a canonical stereotactic
coordinate system. Advanced Normalization Tools (ANTs) provides a highly
accurate

registration

routine

using

symmetric

and

topology-preserving

diffeomorphic deformations to minimize bias toward the reference space and to
capture the deformation necessary to aggregate images in a common space.
Then, we used N4 bias correction to minimize heterogeneity (Tustison et al.
2010) and the ANTs Atropos tool to segment images into six tissue classes
(cortex, white matter, CSF, subcortical grey structures, brainstem, and
cerebellum) using template-based priors and to generate probability maps of
each tissue. Voxel-wise cortical thickness was measured in millimeters (mm)
from the pial surface and then transformed into Montreal Neurological Institute
(MNI) space, smoothed using a 2 sigma full-width half-maximum Gaussian
kernel, and downsampled to 2mm isotropic voxels.
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Neuroimaging analyses.
We used randomise software from FSL to perform nonparametric, permutationbased statistical analyses of cortical thickness images from our ALS and control
neuroimaging cohorts and the ADNI control cohort. Permutation-based statistical
testing is robust to concerns regarding multiple comparisons since, rather than a
traditional assessment of two sample distributions, this method assesses a true
assignment of factors (e.g., genotype) to cortical thickness relative to many (e.g.,
10,000) random assignments (Winkler et al. 2014).
First, we identified regions of reduced cortical thickness in ALS relative to
healthy controls, constraining analysis using an explicit mask restricted to high
probability cortex (>.4). We report clusters that survive p<.005 threshold-free
cluster enhancement (TFCE) (Smith and Nichols 2009) corrected for family-wise
error (FWE) relative to 10,000 random permutations.
Next, we evaluated whether rs12608932 genotype relates to magnitude of
reduced cortical thickness in ALS, covarying for disease duration, age, and sex in
an effort to control for factors associated with reduced cortical thickness but not
specifically associated with SNP genotype. We restricted this analysis to a mask
defined by regions of reduced cortical thickness in ALS relative to controls so that
we could focus our interpretation in the context of cortical degeneration affected
by ALS. We report clusters that survive p<.01 (uncorrected) threshold

and

cluster extent threshold of >20 adjacent voxels relative to 10,000 random
permutations; we employ an uncorrected threshold to minimize the chance of
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Type II error (not observing a true result).
We performed comparable analyses to evaluate SNP genotype relative to
cortical thickness in the ADNI control cohort and adopted the same statistical
thresholds as described above.

Statistical analyses.
All additional statistical analyses were performed using R. For assessment of
ordinal neuropathology data we performed ordinal logistic regression using the
MASS package in R to investigate whether burden of TDP-43 pathology differed
according to genotype at rs12608932, covarying for age, sex, and disease
duration at death. For clinical comparisons, we used multiple linear regression to
evaluate the association between genotype at rs12608932 and performance on
forward and reverse digit span, the MMSE, the VVT, and letter fluency; we
included age, sex, disease duration, ALSFRS-R total score, and cognitive
diagnosis (i.e. diagnosis of ALS-FTD, ALSci) as covariates in each analysis.

Results
Reduced cortical thickness in ALS associated with the rs12608932 minor allele.
A group comparison of ALS patients relative to healthy controls revealed reduced
cortical thickness in the bilateral frontal and temporal lobes, consistent with the
pattern of cortical degeneration associated with ALS-FTD spectrum disorders
(Table 8, Figure 4).
To evaluate disease-specific genotype and neuroanatomic associations
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we restricted our subsequent analyses to regions of reduced cortical thickness
observed in ALS. Evaluation of rs12608932 under a minor allele additive model
revealed reduced cortical thickness associated with the minor allele (C) in the
right anterior temporal lobe, bilateral ventromedial prefrontal cortex, left middle
temporal gyrus, and left dorsal prefrontal cortex (Table 8, Figure 4A). Evaluation
of rs12608932 under a minor allele recessive model revealed reduced cortical
thickness associated with the minor allele (C) in regions including the dorsal and
dorsolateral prefrontal, ventromedial prefrontal, anterior temporal, and middle
temporal cortices (Table 8, Figure 4B).
Investigation of the inverse association between rs12608932 genotype
(i.e. number of major non-risk allele “A”) and cortical thickness yielded no
statistically significant findings for either additive or recessive models (not
shown), suggesting that the rs12608932 minor allele C is specifically associated
with reduced cortical thickness in these regions.
To examine the disease specificity of the relationship between
rs12608932 genotype and reduced cortical thickness in ALS, we performed
comparable analyses in the ADNI control cohort restricted to the same regions of
reduced cortical thickness observed in ALS. We observed no relationship
between cortical thickness and genotype at rs12608932 under minor allele
additive or recessive models (not shown).

Working memory performance associated with rs12608932.
Given the observed association between rs12608932 and frontal and temporal
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cortices, we evaluated each clinical assessment to investigate potential clinical
consequences of the observed neuroanatomic and genetic associations.
We first investigated whether ALSFRS-R relates to rs12608932 genotype.
Under a minor allele additive model, minor allele heterozygotes (AC) (=3.41,
p=.04) but not minor allele homozygotes at rs12608932 (CC) (=1.97, p=.35)
demonstrated higher ALSFRS-R total score compared to major allele
homozygotes (AA); disease duration (=-.037, p=.1), age (=.059, p=.38), sex
(=1.53, p=.33), and cognitive diagnosis (ALSci: =-2.34, p=.37; ALS-FTD: =0.88, p=.62) were not found to significantly affect ALSFRS-R Total in this model.
However, under a minor allele recessive model, we did not observe a significant
difference in ALSFRS-R Total score between minor allele heterozygotes (AC)
and minor allele homozygotes (CC) at rs12608932 (=0.34, p=.87) compared to
major allele homozygotes (AA). To account for the observed difference in
ALSFRS-R under a minor allele additive model, we covaried for ALSFRS-R Total
score in all subsequent regressions.
Under a minor allele additive model, we observed a trend whereby minor
allele homozygotes at rs12608932 (CC) (=-.81, p=.086) performed worse than
major allele homozygotes (AA) on reverse digit span after accounting for
cognitive diagnosis (ALSci: =-1.73, p=.0014; ALS-FTD: =-2.09, p<.00001);
heterozygous genotype (AC) (=.32, p=.38), disease duration (=-.0022, p=.64),
ALSFRS-R total score (=-.012, p=.60), and age (=-.0021, p=.89) did not relate
to reverse digit span performance in this model.
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Under a minor allele recessive model, minor allele homozygotes at rs12608932
(CC) (=-0.96, p=.029) performed significantly worse than major allele
homozygotes (AA) and heterozygotes (AC) on reverse digit span

after

accounting for cognitive diagnosis (ALSci: =-1.69, p=.0017; ALS-FTD: =-2.08,
p<.00001); disease duration (=-.0018, p=.69), ALSFRS-R total score (=-.0013,
p=.95), age (=-.0013, p=.76), and sex (=.55, p=.11), did not significantly relate
to reverse digit span performance in this model.
Performance on other neuropsychological tests was not found to associate with
rs12608932 genotype, including forward digit span (CC: =-.03, p=.93; CA:
=.40, p=.20), letter fluency (CC: =.26, p=.85; CA: =1.61 p=.15), MMSE (CC:
=.036, p=.28; CA: =.006, p=.82), and the VVT (CC: =-.22, p=.67; CA: =-.40,
p=.32). We observed similar results under minor allele recessive models: forward
digit span (CC: =-.22, p=.57), letter fluency (CC: =-.39, p=.76), MMSE (CC:
=.034, p=.26), and the VVT (CC: =.12, p=.80).

pTDP-43 pathologic burden associated with rs12608932.
To evaluate converging evidence for our observed genetic and neuroanatomic
associations, we assessed ordinal neuropathologist ratings of pTDP-43
pathologic burden in the middle frontal, temporal, and motor cortices, which were
associated with rs12608932 in the above neuroimaging analyses (Figure 5).
Minor allele homozygotes (CC) were 8.26 times (95% CI: 2.01, 38.64; p =
.0043) more likely and heterozygotes (AC) were 5.53 times (95% CI: 1.78, 21.21;
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p = .0057) more likely to have higher TDP-43 burden in the middle frontal cortex
relative to major allele homozygotes (AA). Minor allele homozygotes (CC) were
4.40 times (95% CI: 1.25, 16.23; p = .022) more likely to have higher TDP-43
burden in the temporal cortex and – reaching marginal significance - 3.04 times
(95% CI: 0.98, 9.72; p = .056) more likely to have higher TDP-43 burden in the
motor cortex relative to major allele homozygotes (AA); minor allele
heterozygotes (AC) were not more likely to have higher TDP-43 burden relative
to major allele homozygotes in either region (both p values > .1).
We repeated our analysis of TDP-43 pathologic burden in the middle
frontal, temporal, and motor cortices in our autopsy cohort after excluding 21
individuals in the autopsy cohort who were also in the neuroimaging cohort.
Similar to our findings in the entire autopsy cohort, minor allele homozygotes
(CC) were 28.35 times (95% CI: 4.72, 249.31; p = .00064) more likely and
heterozygotes (AC) were 11.49 times (95% CI: 2.78, 78.76; p = .0027) more
likely to have higher TDP-43 burden in the middle frontal cortex relative to major
allele homozygotes (AA). Minor allele homozygotes (CC) were 11.60 times (95%
CI: 2.23, 72.49; p = .005) more likely to have higher TDP-43 burden in the
temporal cortex relative to major allele homozygotes (AA); minor allele
heterozygotes (AC) were not more likely to have higher TDP-43 burden relative
to major allele homozygotes (p > .9). We did not observe any statistically
significant differences in TDP-43 pathologic burden in the motor cortex relative to
rs12608932 in this smaller cohort.
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Discussion
In this study, we evaluated whether rs12608932 genotype in UNC13A was
associated with frontotemporal disease in sporadic ALS using a novel multimodal
approach integrating genetic, neuroimaging, clinical, and neuropathology data.
Our results indicate that sporadic ALS patients who are carriers of the
rs12608932 minor allele (C) show reduced cortical thickness in regions including
the dorsal and ventromedial prefrontal cortex, anterior and middle temporal
cortex, and premotor cortex, and that minor allele homozygotes (CC)
demonstrate worse performance on reverse digit span, a frontal-lobe mediated
cognitive test. We did not observe a relationship between rs12608932 genotype
and cortical thickness in the amyloid-negative ADNI healthy control cohort,
suggesting that the association between rs12608932 and reduced cortical
thickness is specific to ALS. Furthermore, in our sporadic ALS autopsy cohort,
we demonstrate that carriers of the rs12608932 minor allele have increased odds
of pTDP-43 pathologic burden in the middle frontal cortex, middle temporal
cortex, and motor cortex, consistent with our neuroimaging findings. To our
knowledge, our study provides novel evidence that the minor allele of
rs12608932 in UNC13A is associated with in vivo frontotemporal cortical atrophy,
impaired cognitive performance, and greater burden of pTDP-43 pathological
inclusions in sporadic ALS.
rs12608932 was first identified through a two-stage GWAS as a
susceptibility locus for sporadic ALS with a combined P = 2.53 x 10(-14) (van Es
et al. 2009). rs12608932 maps to a haplotype block within the boundaries of
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gene UNC13A, which regulates presynaptic vesicle priming and glutamate
release at neuromuscular synapses, and mice lacking the UNC13A homolog
have arrested synaptic vesicle maturation and disrupted glutamatergic
transmission (Augustin et al. 1999). Subsequent population-based study
indicated the minor allele (C) at rs12608932 as a risk factor for shorter survival in
sporadic ALS under both additive and recessive models (Diekstra et al. 2012;
Chiò et al. 2013; Vidal-Taboada et al. 2015), and as a modifier of physical
symptom progression on the ALSFRS-R (Vidal-Taboada et al. 2015). In addition
to risk and progression of sporadic ALS, rs12608932 was also identified to serve
as a risk locus for sporadic FTLD-TDP (Diekstra et al. 2014), suggesting
rs12608932 as a potential link between ALS and FTLD-TDP. More recently, an
additional SNP in UNC13A in high LD with rs12608932 (rs4239633; D’=0.83)
was identified as demonstrating selective genetic overlap between ALS and FTD
in GWAS meta-analysis (Karch et al. 2018).
Our findings corroborate rs12608932 as a genetic link between ALS and
FTD with TDP-43 pathology, and specifically demonstrate that the minor allele is
associated with reduced cortical thickness, worse working memory performance,
and greater burden of TDP-43 pathology in the frontal and temporal lobes.
Importantly, we use continuous disease traits from multiple modalities (i.e.
structural imaging, cognitive testing, neuropathology data) to present converging
evidence that rs12608932 confers increased risk of frontotemporal disease in
sporadic ALS and relates to patient cognitive performance. This approach offers
an advance over discovery GWAS that compare only categorical clinical
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designations (e.g. ALS vs. healthy controls), and allows detailed phenotypic
characterization associated with rs12608932 genotype.
Furthermore,

the observed

relationship between

rs12608932

and

both

frontotemporal cortical thinning and burden of TDP-43 pathology are consistent
with the disease anatomy of ALS-FTD spectrum disorders. Structural MRI
studies have previously demonstrated progressive frontotemporal gray matter
degeneration over disease course (Menke et al. 2014; Verstraete et al. 2014;
Kwan et al. 2013; Verstraete et al. 2012; Keil et al. 2012; Senda et al. 2011;
Müller et al. 2016), and that degree of frontotemporal cortical thinning relates to
cognitive-behavioral phenotype (Agosta et al. 2016; Schuster et al. 2014).
Additionally,

staging

of

neuropathological

burden

suggests

stereotyped

propagation of TDP-43 from motor regions (brainstem, spinal cord) to frontal and
temporal neocortex over the course of disease (Brettschneider et al. 2013; Braak
et al. 2013). Our finding of greater TDP-43 pathologic burden associated with the
rs12608932 in frontal and temporal neocortex may thus be interpreted to reflect
more progressive disease propagation in sporadic ALS patients who are minor
allele carriers. This finding could also be related to TDP-43 pathologic subtype
(Mackenzie et al. 2011), and future work is necessary to 1) evaluate the influence
of TDP-43 pathologic subtype on the anatomic distribution and phenotypic
presentation (e.g. comorbid symptoms of frontotemporal disease) of disease, and
2) investigate how rs12608932 genotype relates to TDP-43 pathologic subtype.
With this in mind, rs12608932 genotype may potentially be used prognostically to
evaluate risk of frontotemporal cortical disease in ALS, which has been
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previously associated with reduced survival (Govaarts et al. 2016; Elamin,
Phukan, Bede, Jordan, Byrne, Pender, and Hardiman 2011b).
The observed relationships between rs12608932, reduced cortical
thickness in the dorsal and ventromedial prefrontal cortices, and worse
performance on reverse digit span are congruent with the neuroanatomy of
working memory. Indeed, functional activation of the dorsal and ventromedial
prefrontal cortices relates to memory load function and information retrieval on
tasks of working memory, respectively (Rypma and D’Esposito 1999).
We also observed a relationship between rs12608932 and reduced
cortical thickness in the right orbital frontal cortex, right anterior temporal lobe,
and left middle temporal gyrus. Our group has previously shown that reduced
cortical thickness in the orbital frontal cortex is associated with behavioral
disinhibition and apathy in patients with FTD (Massimo et al. 2009), while others
have shown that cortical thinning in the right anterior temporal lobe and left
middle temporal gyrus are associated with impaired semantic knowledge and
theory of mind in patients with FTD (Irish, Hodges, and Piguet 2014; Rohrer et al.
2009). Impairments in behavior and language are common to both ALS and FTD
(Beeldman et al. 2018), and prospective studies are necessary to evaluate
potential rs12608932 associations relative to language and behavioral function
using more comprehensive neuropsychological batteries like the Edinburgh
Cognitive Assessment Scale (ECAS) (Abrahams et al. 2014), which were not
available in this retrospective study.
Our findings add to an increasing body of evidence in support of a
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clinicopathologic continuum between ALS and FTD with underlying TDP-43
pathology, and specifically suggest that genetic polymorphisms may relate to the
phenotypic presentation of frontotemporal disease in sporadic ALS. This is
consistent with prior work from our group demonstrating that TDP-43 pathologyassociated SNPs relate to selective neuroanatomic distribution of cortical atrophy
and white matter degeneration in patients with sporadic forms of FTD (McMillan
et al. 2014), modify disease onset and survival in FTD with C9ORF72 repeat
expansions (“TMEM106B is a Genetic Modifier of Frontotemporal Lobar
Degeneration with C9ORF72 Hexanucleotide Repeat Expansions (I5-1.008),”
2014) (Gallagher et al. 2014), and confer risk for impaired executive function in
ALS (Vass et al. 2011).
The identification of genetic polymorphisms associated with disease
phenotypes holds important implications for both basic science research and
translational application. Our observed association between rs12608932 and
frontotemporal disease in sporadic ALS motivates further investigation into
potential

mechanisms

of

disease

vulnerability

associated

with

genetic

polymorphisms. While the function of gene UNC13A has previously been
characterized (Augustin et al. 1999), future work is necessary to determine the
extent to which rs12608932 genotype provides an actual disease modifier or is
an association related to matching downstream transcription sites or other longrange interactions (Haiquan Li et al. 2016). In regards to translational application,
our findings may contribute to patient stratification for clinical trials. Prior research
has demonstrated baseline differences in patients stratified for SNP genotype
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and indicate a contribution of genetic polymorphisms in dose-response to
treatment (D. Wang et al. 2011), leading to the incorporation of genetic
polymorphisms in the design and analysis of clinical trials (Zhang et al. 2017).
Several caveats should be considered in the present study. Our data were
limited according to strict inclusion criteria to investigate the clinical, pathologic,
and regional anatomical differences in sporadic ALS patients relative to
rs12608932 genotype. While we establish multiple sources of converging
evidence for rs12608932 genotype relating to frontal disease, replication of the
present findings in a large independent cohort using a prospective design is
necessary. Furthermore, additional research is required to determine the extent
to which pTDP-43 pathological burden directly or indirectly relates to reductions
in cortical thickness. In this study, our evaluation of cognitive performance was
retrospective and limited to measures broadly assessing executive function and
global

cognition.

Future

studies

using

revised

diagnostic

criteria

for

frontotemporal dysfunction in ALS (Strong et al. 2017) and specialized
assessment of cognitive function in patients with ALS, such as the Edinburgh
Cognitive and Behavioral ALS Screen (Abrahams et al. 2014), are necessary to
also assess impairments in other domains including language and behavior.
Here, we focus on genetic contributions to frontotemporal disease in sporadic
ALS. However, environmental factors such as those associated with cognitive
reserve

have

been

demonstrated

to

influence

frontotemporal

disease

neuroanatomy in FTD (Massimo et al. 2018; Massimo et al. 2015; Placek et al.
2016), also when considered in addition to genetic polymorphisms (Premi et al.
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2017). Additional study is necessary to examine frontotemporal disease in
sporadic ALS relative to both genetic polymorphisms and environmental factors
associated with cognitive reserve.
With these caveats in mind, our research demonstrates converging
clinical, neuroimaging, and pathologic evidence supporting the hypothesis that
the common genetic polymorphism rs12608932 contributes to frontotemporal
disease phenotype in sporadic ALS. These findings stimulate investigation into
additional genetic contributors to the nature of disease in sporadic ALS, and
suggest their importance in prognostic consideration and treatment trials in
patients with ALS.
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Table 6. Demographic, clinical, and genetic information for neuroimaging and
ADNI cohorts.
N (F)
Age, Y
Education, Y
Race, N
White
Black
Multi-racial
Other
Unknown
Ethnicity, N
Latino
Non-Latino
Other
Unknown
Disease duration, M
ALSFRS-R
Forward digit span,
% impaired
Reverse digit span,
% impaired
Letter fluency,
% impaired
Visual Verbal Test,
% impaired
MMSE, % correct,
% impaired
rs12608932 genotypes, N
AA
AC
CC

ALS
109 (44)
59.54 (10.96)
15.26 (2.99)

Controls
113 (52)
61.54 (8.73)
15.35 (2.43)

ADNI Controls
84
75.44 (6.40)
-

100
6
1
1
1

90
22
1
-

2
105
1
1
38.67 (34.25)
33.81 (7.39)
6.53 (1.45),
4.54
4.21 (1.70),
13.63
11.29 (5.41),
23.86
7.8 (4.13),
9.09
91.82 (14.11),
25.00

1
111
1
-

-

-

-

-

-

-

-

-

-

43
46
20

-

41
34
9

-

Abbreviations: Alzheimer’s Disease Neuroimaging Initiative – ADNI; ALS
Functional Rating Scale-Revised - ALSFRS-R; Mini-Mental State Exam – MMSE
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Table 7. Demographic, clinical, and genetic information for autopsy cohort.

N (F)
Age at Death, Y
Race, N
White
Black
Multi-racial
Other
Unknown
Ethnicity, N
Latino
Non-Latino
Other
Unknown
Education, Y
Disease duration at Death,
Y
rs12608932 genotypes, N
AA
AC
CC

ALS (entire cohort)
102 (40)
65.01 (10.83)

ALS
(no neuroimaging)
81 (29)
66.21 (10.99)

71
3
1
27
2
72
28
15.18 (3.48)
4.83(4.98)

14.76 (3.44)
4.87(5.42)

38
47
17

30
39
12
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Table 8. Regions of reduced cortical thickness for ALS relative to controls and
associated with rs12608932 genotype in ALS.
Neuroanatomic region (BA)

L MNI Coordinates
/
x
y
z
R
Reduced cortical thickness in ALS relative to controls1:
Insular Cortex (13)

R

40

22

Inferior Frontal Gyrus (45)

L

-32

Dorsolateral Prefrontal Cortex (9)

-

0

Inferior Frontal Gyrus (45)

R

T
statistic

p
value

Voxels

25627

0

6.72

0.0006

28

2

6.18

0.0001

46

18

6.12

0.0001

34

22

8

5.96

0.0007

Ventromedial Orbital Frontal Cortex (11)

R

12

14

-20

5.91

0.0001

Ventromedial Orbital Frontal Cortex (11)

L

-12

14

-18

5.79

0.0001

Middle Temporal Gyrus (21)

R

64

-32

10

3.54

0.004

Reduced cortical thickness associated with rs12608932 minor allele in ALS: Additive model
Anterior Temporal Lobe (38)

R

34

10

-40

3.08

0.002

56

Ventromedial Prefrontal Cortex (11)

L

Middle Temporal Gyrus (22)

L

-20

26

-24

3.21

0.001

27

-50

-10

-12

2.88

0.003

24

Dorsal Prefrontal Cortex (10)

L

-28

44

28

3.56

0.001

23

Ventromedial Prefrontal Cortex (11)

R

16

16

-24

3.66

0.001

21

Reduced cortical thickness associated with rs12608932 minor allele in ALS: Recessive model
Anterior Temporal Lobe (20)

R

30

10

-44

3.50

0.001

238

Middle Temporal Gyrus (21)

L

-50

-10

-14

4.04

0.001
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Anterior Temporal Lobe (20)

L

-56

-8

-28

3.56

0.001

62

Premotor Cortex (6)

L

-50

2

42

3.90

0.001

52

Dorsolateral Prefrontal Cortex (9)

R

32

48

34

3.23

0.001

44

Primary Motor Cortex (4)

R

48

-12

40

3.07

0.001

39

Superior Temporal Cortex (22)

R

66

-36

10

3.30

0.001

35

Orbital Prefrontal Cortex (11)

R

8

34

-8

2.81

0.001

31

Orbital Prefrontal Cortex (11)

L

-20

30

-24

3.23

0.001

31

Ventromedial Prefrontal Cortex (47)

R

30

22

4

3.45

0.001

30

Hippocampus (54)

R

30

-38

2

2.56

0.003

30

Insula (13)

R

36

-12

2

2.88

0.001

29

Anterior Premotor Cortex (8)

R

36

28

48

4.00

0.001

25

Dorsal Prefrontal Cortex (10)

L

-34

52

16

3.16

0.001

25

Middle Temporal Gyrus (21)

R

50

8

-20

2.97

0.003

25

Abbreviations: BA = Brodmann area; L/R = Left/Right; MNI = Montreal
Neurological Institute
Note.1 Cortical regions identified from peak voxel coordinates in an effort to
describe sub-peaks within a larger, contiguous cluster.
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Figure 4. Reduced cortical thickness associated with rs12608932 genotype.
Analyses were restricted to regions of reduced cortical thickness identified in
sporadic ALS (N=109) relative to healthy controls (N= 113) (light blue regions in
A and B). A) Patients with sporadic ALS who are carriers of the minor allele (C)
exhibited greater reduction of cortical thickness in dorsal prefrontal, ventromedial
prefrontal, anterior temporal, and middle temporal cortices (regions indicated in
red-yellow heatmap). B) Patients with sporadic ALS who are homozygous (CC)
or heterozygous (AC) for the minor allele exhibited greater reduction of cortical
thickness in the frontal and temporal cortices (regions indicated in red-yellow
heatmap). Heatmaps indicate the associated T-statistic for each voxel, with
yellow representing the highest value.
A

0.0

3.66

B

0.0

4.04

AC
AA
CC
0

1

2

3

AA

AC

Middle frontal cortex

rs12608932

Motor cortex

CC

AA

AC

Temporal cortex

CC
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Figure 5. Greater burden of pTDP-43 pathology associated with rs12608932
genotype. Box and whisker plots of pTDP-43 pathologic burden in our sporadic
ALS autopsy cohort (N=102) show that minor allele homozygotes (CC) and
heterozygotes (AC) feature greater burden of pathology in the middle frontal
cortex. Minor allele homozygotes but not minor allele heterozygotes also feature
greater burden of pathology in the superior/middle temporal cortex and motor
cortex.
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CHAPTER 4
Machine learning suggests polygenic contribution to cognitive dysfunction
in amyotrophic lateral sclerosis
Katerina Placek, Michael Benatar, Joanne Wuu, Evadnie Rampersaud, Laura
Hennessy, Vivianna M. Van Deerlin, Murray Grossman, David J. Irwin, Lauren
Elman, Leo McCluskey, Colin Quinn, Volkan Granit, Jeffrey M. Statland, Ted. M
Burns, John Ravits, Andrea Swenson, Jon Katz, Erik Pioro, Carlayne Jackson,
James Caress Yuen So, Samuel Maiser, David Walk, Edward B. Lee, John Q.
Trojanowski, Philip Cook, James Gee, Jin Sha, Adam C. Naj, Rosa Rademakers,
The CReATe Consortium, Wenan Chen, Gang Wu, J. Paul Taylor and Corey T
McMillan. Under Review.

Abstract
Amyotrophic lateral sclerosis (ALS) is a multi-system disease characterized
primarily by progressive muscle weakness. Cognitive/behavioral dysfunction is
observed in as many as 50% of patients, however factors influencing risk for
cognitive dysfunction remain elusive. Using sparse canonical correlation analysis
(sCCA), an unsupervised machine-learning technique, we observed that single
nucleotide

polymorphisms

collectively

associate

with

baseline

cognitive

performance in 327 ALS patients from the multicenter Clinical Research in ALS
and Related Disorders for Therapeutic Development (CReATe) consortium. We
demonstrate that a polygenic risk score derived using sCCA relates to
longitudinal cognitive decline in the same cohort, and also to in vivo cortical
thinning in the orbital frontal cortex, anterior cingulate cortex, lateral temporal
cortex, premotor cortex, and hippocampus (N=114); as well as post mortem
motor cortical neuronal loss (N=88) in independent ALS cohorts from the
University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Our
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findings suggest that common genetic polymorphisms may exert a polygenic
contribution to the risk of cortical disease vulnerability and cognitive dysfunction
in ALS.

Introduction
As many as half of patients with amyotrophic lateral sclerosis (ALS) manifest
progressive decline in cognition consistent with extra-motor frontal and temporal
lobe neurodegeneration, including 14% also diagnosed with frontotemporal
dementia (FTD) (Montuschi et al. 2015; Beeldman et al. 2016). Comorbid
cognitive dysfunction is a marker of poorer prognosis in this fatal disease and
confers risk for more rapid functional decline, shorter survival, and greater
caregiver burden (Elamin et al. 2013; Crockford et al. 2018; Hu et al. 2013; Caga
et al. 2019). While linkage analysis and genome-wide association studies
(GWAS) have identified rare causal mutations (DeJesus-Hernandez et al. 2011;
Renton et al. 2011; Van Deerlin et al. 2008; Freischmidt et al. 2015) and common
risk loci (van Rheenen et al. 2016; Nicolas et al. 2018; van Es et al. 2009;
Diekstra et al. 2014; Karch et al. 2018) linking ALS and FTD, whether and how
identified variants relate to phenotypic heterogeneity, including in cognition,
remain largely unexplored.
The genetic landscape of ALS is largely characterized by ‘apparently
sporadic’ disease occurring in 90% of patients with neither a known family
disease history nor an identifiable pathogenic mutation (Turner et al. 2017).
Population-based studies estimate that only 5-10% of non-familial and 40-50% of
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familial ALS cases can be attributed to known pathogenic mutations (Umoh et al.
2016) (e.g. C9ORF72 (Renton et al. 2011; DeJesus-Hernandez et al. 2011),
NEK1 (Kenna et al. 2016), SOD1 (D. R. Rosen et al. 1993)), but GWAS have
revealed many loci of common genetic variation that confer risk for ALS and
FTD. Indeed, recent evidence, supports a polygenic contribution to disease risk
from common genetic variants (McLaughlin et al. 2017; Ciga et al. 2019). These
include the largest ALS GWAS to-date which newly identified risk variants in the
KIF5A gene (Nicolas et al. 2018), and genome-wide conjunction and conditional
false discovery rate (FDR) analyses demonstrating shared genetic contributions
between ALS and FTD from common single nucleotide polymorphisms (SNPs) at
known and novel loci (Karch et al. 2018).
An accumulating body of research suggests that SNPs associated with
risk of ALS and FTD demonstrate quantitative trait modification of patient
phenotype. For example, a SNP in identified as a risk locus for ALS and FTD
was found to contribute to cognitive decline, in vivo cortical degeneration in the
prefrontal and temporal cortices, and post mortem pathologic burden of
hyperphosphorylated TAR-DNA binding protein [43 kDa] (TDP-43) in the middle
frontal, temporal, and motor cortices (Placek et al. 2019). Another SNP identified
as a risk locus for FTD with underlying TDP-43 pathology was additionally
associated with cognition in patients with ALS (Vass et al. 2011). Others have
recently demonstrated shared polygenic risk between ALS and other traits (e.g.
smoking, education) and diseases (e.g. schizophrenia) (Ciga et al. 2019;
McLaughlin et al. 2017; Hagenaars et al. 2018), suggesting that a single variant
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is unlikely to fully account for observed disease phenotype modification.
Presently there are no published studies evaluating polygenic contribution to
cognitive dysfunction in ALS.
Here we employed an unsupervised machine-learning approach, sparse
canonical correlation analysis (sCCA), to identify and evaluate a potential
polygenic contribution to cognitive dysfunction in ALS. Traditional approaches for
constructing polygenic scores identify variants associated with disease risk
through GWAS in a univariate manner, and then compute the sum of alleles at
each identified variant, weighted by their effect sizes. In this study, we used datadriven sCCA to identify polygenic associations with a continuous phenotype of
cognitive performance in ALS. This method employs sparsity to select maximallycontributing variants and assigns corresponding weights based on model
contribution with minimal a priori assumptions. We used sCCA to derive a
polygenic risk score for cognitive dysfunction in a large longitudinal cohort of
cognitively characterized patients with ALS or a related disorder participating in
the Phenotype-Genotype-Biomarker (PGB) study of the Clinical Research in ALS
and Related Disorders for Therapeutic Development (CReATe) consortium. We
then evaluated independent neuroimaging and autopsy cohorts of patients with
ALS from the University of Pennsylvania Integrated Neurodegenerative Disease
Biobank (UPenn Biobank) (Toledo et al. 2014) to evaluate whether polygenic risk
for cognitive dysfunction also relates to in vivo cortical neurodegeneration and ex
vivo cortical neuronal loss and TDP-43 pathology. We focused our investigation
on SNPs achieving genome-wide significance in the largest published ALS
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GWAS (Nicolas et al. 2018), and SNPs identified as shared risk loci for both ALS
and FTD (Karch et al. 2018). We hypothesized that a sparse multivariate
approach would reveal a subset of genetic loci associated with cognitive
dysfunction profiles in ALS in a polygenic manner, and that follow-up analyses in
independent neuroimaging and autopsy cohorts would converge to characterize
quantitative traits associated with polygenic risk from identified loci.

Results
Heterogeneity of baseline cognitive and motor phenotype in ALS patients.
Smaller-scale studies have shown that ALS patients have impairments in
executive, verbal fluency, and language domains, but with relative sparing of
memory and visuospatial function (Crockford et al. 2018). The Edinburgh
Cognitive and Behavioral ALS Screen (ECAS) was developed to measure
cognitive function minimally confounded by motor disability and includes an
“ALS-Specific” score that captures impairments in language, executive function,
and verbal fluency domains that are frequently observed in ALS patients, and an
“ALS-Non-Specific” score that captures less frequently observed impairments in
memory and visuospatial function, in addition to overall performance (ECAS
Total score) (Abrahams et al. 2014). To measure the extent of heterogeneity in
cognitive dysfunction, we evaluated 327 patients with ALS or a related disorder
(e.g., ALS-FTD, primary lateral sclerosis (PLS), progressive muscular atrophy
(PMA))

participating

in

the

PGB

study

of

the

CReATe

consortium

(NCT02327845) (Table 9). We used linear mixed-effects (LME) to model
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variability between individuals in baseline performance and rate of decline on the
ECAS (Total Score, ALS-Specific Score, ALS-Non-Specific Score, and scores for
each individual cognitive domain), and on clinical measures of physical disability
on the ALS Functional Rating Scale – Revised (ALSFRS-R), and clinician ratings
of upper motor neuron (UMN) and lower motor neuron (LMN) symptom severity;
each model included covariate adjustment for potential confounders including
age, education, bulbar onset, and disease duration. We confirmed that cognitive
and motor performance at baseline are heterogeneous across individuals (Figure
6A), and correlation analyses suggested that this is independent of disability in
physical function or clinical burden of UMN/LMN signs (all R<0.2; Figure 6B).
Together this establishes the heterogeneity of baseline and longitudinal cognitive
and motor phenotypes within the PGB cohort.

Multivariate analyses indicate polygenic contributions to baseline cognitive
performance.
To identify potential polygenic contributions to cognitive impairment in ALS we
employed sCCA (Witten, Tibshirani, and Hastie 2009), an unsupervised
machine-learning approach enabling identification of multivariate relationships
between a dataset of one modality (e.g. genetic variables including allele dosage
of SNPs) and another modality (e.g. clinical measures of motor and cognitive
function). Traditional CCA identifies a linear combination of all variables that
maximize the correlation between datasets, resulting in an association of
variables from one dataset (e.g., SNPs) and variables from another dataset (e.g.,
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clinical scores) (Witten, Tibshirani, and Hastie 2009). The “sparse” component of
sCCA additionally incorporates an L1 penalty that shrinks the absolute value of
the magnitude of coefficients to yield sparse models (i.e. models with fewer
variables) such that some coefficients are zero, and the variables associated with
them are effectively eliminated from the model. As a result, variables that
contribute little variance to the model are dropped and instead of a linear
combination of all model variables, we are able to identify a data-driven subset of
variables from one dataset that relate to a subset of variables from another
dataset. Unstandardized regression coefficients resulting from sCCA serve as
canonical weights indicating the direction and strength of the relationships
between selected variables.
We evaluated an allele-dosage dataset comprised of 33 SNPs identified
as shared risk loci for both ALS and FTD (Karch et al. 2018), and 12 SNPs
identified as risk loci for ALS from the largest published case-control GWAS
(Nicolas et al. 2018), with the latter chosen to include loci associated with ALS
but not specifically with FTD (Figure 6C; Table 11). We included the first two
principle components from a PCA and binary variables for sex, C9ORF72 repeat
expansion status, and other mutation status (e.g. SOD1) in this dataset to
account for inter-individual genetic differences in population structure, sex, and
mutation status. We then used sCCA to examine the association between this
genetic dataset and a dataset comprised of adjusted baseline clinical
performance on functional motor and cognitive measures extracted from LME
models.
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After optimizing model sparsity parameters (Figure 7), we ran sCCA
10,000 times and employed random bootstrapped subsamples of 75% of
participants in each iteration (Figure 8). We then calculated the median canonical
correlation, the median canonical weight for each genetic variable, and the
proportion of times each clinical feature was chosen out of 10,000 iterations as a
percentage. We report percentages rather than median canonical weight for
clinical features because the optimized L1 parameter for the clinical dataset was
the most stringent (i.e. 0.1), thus resulting in only one variable from the clinical
dataset being chosen in each of the 10,000 iterations.
To assess model performance under the null hypothesis (no association
between genetic factors and clinical phenotypes), we similarly ran 10,000
bootstrap sCCAs using the same L1 and subsampling parameters and in each
model iteration we randomly permuted each dataset 100 times. We also
examined the proportion of times each variable was selected by this null model
(i.e. achieving a non-zero canonical weight), and defined a p value for the true,
unpermuted model by calculating the probability of observing a canonical
correlation greater than or equal to the median canonical correlation under sCCA
modeling of the true data relative to the canonical correlations observed under
null sCCA modeling of randomly permuted data.
We observed that a subset of 29 genetic variables were correlated with a
single clinical feature, achieving a median canonical correlation between the two
datasets of R=0.35 (95% Confidence Interval: 0.23, 0.42); p=0.019) (Figure 9,
Figure 10). Over the 10,000 iterations, the most frequently selected clinical
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variable was the ECAS ALS-Specific score (percentage of times selected: 37%),
followed by the ECAS Total (29%), Executive Function (17%), Language (9.5%),
Verbal Fluency (2.3%), ALS-Specific (2.2%), Memory (2%), and Visuospatial
(0.34%) scores. The ALSFRS-R and UMN and LMN assessments were each
selected in less than 0.05% of the model iterations. By contrast, performance of
sCCA modeling under the null hypothesis demonstrated that each clinical
variable was selected in a largely equal proportion of iterations (all variables
ranging 5.9% to 9.4%), demonstrating that the true sCCA modeling selected
cognitive and not motor features beyond what would be expected by chance
(Figure 11A).
Of the 29 selected genetic variables, the 12 most highly weighted were
rs1768208 and rs9820623 (MOBP), rs7224296 (NSF), rs538622 (ERGIC1),
rs10143310 (ATXN3), rs6603044 (BTBD1), rs4239633 (UNC13A), rs2068667
(NFASC), rs10488631 (TNPO3), rs11185393 (AMY1A), rs3828599 (GPX3), and
sex. Twenty-seven of the 29 genetic variables selected were SNPs, and 85% of
model-selected SNPs (23/27) were shared risk loci for ALS and FTD (Karch et al.
2018). Modeling under the null revealed that each genetic variable achieved a
largely equal median weight, and thus there were no stronger model
contributions from any subset of genetic variables (Figure 11B). The association
of genetic variants most frequently with the ECAS ALS-Specific score suggests
polygenic contribution to impairment in domains of cognition frequently impaired
in patients with ALS (e.g. language, verbal fluency, and executive function) that
are also the most impaired domains of cognition observed in FTD.
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Polygenic score captures baseline cognition as well as longitudinal rate of
cognitive decline, but not motor decline.
Next we investigated potential polygenic contributions to rate of decline in motor
and cognitive performance in the CReATe PGB cohort. Investigation of baseline
performance may only capture differences in cognitive impairment at a single
(somewhat arbitrary) point in time, but not differences in the trajectory of
cognitive decline over time.
To evaluate association with longitudinal decline, we first calculated a
weighted polygenic score (wPGS) by computing a weighted sum of allele dosage
for each individual multiplied by the median canonical weights for each genetic
variant resulting from the prior sCCA. Spearman rank-order correlations between
the wPGS and adjusted baseline estimates of the 4 clinical features selected in
10% or more of the 10,000 iterations (e.g. ECAS ALS-Specific, Total, Executive
Function, and Language scores) resulted in correlation values similar to the
canonical correlation observed from sCCA (e.g. for ECAS ALS-Specific:
rs(329)=-0.34, p=2.4×10-10) (Figure 12A), suggesting construct validity.
We then conducted Spearman’s rank order correlations between the
wPGS and adjusted rate of decline on each measure of cognitive and motor
performance using a Bonferroni family-wise error correction. To obtain adjusted
rates of decline, we extracted individual slope estimates from prior LME (see
above) for the 277 individuals (85%) with 2 or more observations on the ECAS,
ALSFRS-R, and UMN and LMN assessments. We observed significant negative
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relationships between the wPGS and rate of decline on ECAS ALS-Specific
(rs(277)=-0.21, p=5.3×10-3), ALS-NonSpecific (rs(277)=-0.19, p=0.016), and
Total scores (rs(277)=-0.26, p=8.1×10-5) (Figure 12B), but not on the ALSFRS-R
or UMN and LMN scores (all p >0.9). These findings suggest polygenic
contribution to rate of cognitive – but not motor – decline from the SNPs
associated with risk of ALS or joint risk of ALS and FTD that were included in this
analysis.

Polygenic score associates with cortical thinning in the UPenn Biobank.
Cognitive dysfunction in ALS, including performance on the ECAS, has
previously been attributed to sequential disease progression rostrally and
caudally from the motor cortex (Lulé et al. 2018; Agosta et al. 2016; Müller and
Kassubek 2018) and advancing disease stage (Crockford et al. 2018). To
evaluate the neuroanatomic basis for polygenic contribution to cognitive
performance in patients with ALS, we applied the wPGS score derived in the
CReATe PGB Cohort to an independent cohort of patients with ALS from the
UPenn Biobank.

We used voxel-wise in vivo measures of reduced cortical

thickness (in mm3) in ALS patients. Cross-sectional measurements of cortical
thickness were derived from T1-weighted magnetic resonance imaging (MRI) in
114 patients with ALS and 114 age, sex, and education-matched healthy controls
who were recruited for research from UPenn (Table 10A). Nonparametric
modeling using 10,000 random permutations revealed extensive reduction of
cortical thickness bilaterally in the frontal and temporal cortices of patients with
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ALS relative to healthy controls (Table 12, Figure 13A).
After identifying regions of reduced cortical thickness in patients with ALS,
we investigated whether the wPGS derived from sCCA modeling in the CReATe
PGB cohort contributed to magnitude of reduced cortical thickness in the
independent UPenn Biobank neuroimaging cohort. Nonparametric modeling
using 10,000 random permutations with adjustments for potential confounds in
age, disease duration, and scanning acquisition revealed that a higher wPGS
(i.e. greater risk) associated with reduced cortical thickness in the orbital
prefrontal cortex, anterior cingulate cortex, premotor cortex, lateral temporal
cortex, and hippocampus (Figure 13B, Table 12). Identified frontal and temporal
lobe cortical regions are known to support the domains of cognitive dysfunction
characterized by the ECAS (Lulé et al. 2018). These findings provide a potential
neuroanatomical basis for observed polygenic relationships between the wPGS
and baseline cognitive performance and rate of decline, and are consistent with
prior associations of cortical neurodegeneration with cognitive dysfunction in
patients with ALS (Agosta et al. 2016).

Polygenic score associates with neocortical neuronal loss in the UPenn Biobank.
To complement these in vivo neuroanatomical data, we also explored whether
polygenic risk for cognitive dysfunction associated with post-mortem anatomical
distribution of neuronal loss and TDP-43 pathology. We assessed the magnitude
of neuronal loss and TDP-43 pathological inclusions on an ordinal scale in tissue
sampled from the middle frontal, cingulate, motor, and superior / middle temporal
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cortices in 88 autopsy cases with confirmed ALS due to underlying TDP-43
pathology (Table 10B). We conducted ordinal logistic regression with covariate
adjustment for age at death and disease duration and found that ALS cases with
higher wPGS were 2.05 times more likely (95% CI: 1.05, 4.10; p=0.0043) to have
greater neuronal loss in the motor cortex relative to ALS cases with a lower
wPGS (Figure 13C); older age at death and longer disease duration were not
found to influence likelihood of greater neuronal loss (both p>0.05). We observed
no statistically significant associations between the wPGS and neuronal loss in
any other region, or between the wPGS and TDP-43 pathology in any other
region (all p values >.1). These findings suggest that polygenic risk for cognitive
dysfunction is associated with the neuroanatomic distribution of neuronal loss in
ALS cases with end-stage disease.

Discussion
In this study, we evaluated polygenic contributions to cognitive dysfunction in
patients with ALS by employing machine learning. We identified polygenic risk for
cognitive dysfunction from genetic variables associated with risk of ALS and
FTD, which we further investigated through quantitative-trait evaluations of two
independent ALS cohorts with in vivo neuroimaging and post-mortem
neuropathology data. Our results indicate a polygenic contribution to the
presence and rate of decline of cognitive dysfunction in domains specifically
impaired in ALS. Converging evidence from independent cohorts further
demonstrates the generalizability of polygenic contribution to biologically-
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plausible associations including reduced in vivo cortical thickness and postmortem cortical neurodegeneration, including in the prefrontal and temporal
cortices. These findings contribute novel evidence in support of polygenic
contribution

to

cognitive

dysfunction

in

ALS,

quantitative

anatomic

characterization of identified polygenic risk associated with cognitive dysfunction,
and further detailed phenotypic evidence for genetic overlap between ALS and
FTD. Below, we highlight clinical, biological, and methodological implications for
our observations.
Our findings add to an increasing body of evidence for genetic contribution
to phenotypic variability in ALS, and support the idea that polygenic variation
accounts for, at least a portion, of variability in cognitive dysfunction and cortical
disease burden in ALS. While cognitive impairment has been more frequently
linked to genetic mutations causally associated with ALS, such as C9ORF72
repeat expansions (Byrne et al. 2012), studies examining individual variants have
implicated SNPs as risk factors for ALS and/or FTD (Placek et al. 2019; Vass et
al. 2011). However, mounting evidence suggests that there are polygenic, rather
than single allele, modifiers of disease risk and phenotype in ALS and related
neurodegenerative diseases (Hagenaars et al. 2018; McLaughlin et al. 2017;
Ciga et al. 2019). Our observation of 27 SNPs collectively associated most
frequently with the ECAS ALS-Specific score, a combined measure of executive,
language, and verbal fluency domains most commonly affected in ALS, is
consistent with the idea of polygenic contribution to phenotypic variability in ALS.
Notably, our observed polygenic association in the CReATe PGB Cohort appears
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specific to cognitive variability: we demonstrate relative independence of
cognitive performance and motor disease severity (i.e. UMN or LMN symptom
assessments, functional performance on the ALSFRS-R) and observe no
evidence for polygenic association with motor disease severity. This suggests
that, in this study, polygenic risk for cognitive dysfunction does not appear to be
confounded by motor disease severity.
Of the 27 identified SNPs, the majority (85%) are shared risk loci for ALS
and FTD (Karch et al. 2018). SNPs in or near the MOBP, NSF, ATXN3, ERGIC1,
and UNC13A genes were among those with the strongest model contributions
(i.e. with the highest canonical weights). Relative to random permutations, the
frequency of the selection of these ALS and FTD loci outweighed their selection
by chance and outweighed the selection of ALS-only risk genotypes,
emphasizing the relative contribution of polygenic overlap between ALS and
FTD. Furthermore, these results suggest a conceptual distinction between
genetic risk for disease and genetic risk for phenotypic differences within a
disease. Two of these loci in or near the MOBP gene (rs9820623, rs1768208)
were amongst the most heavily weighted. Our group has previously shown that
SNPs

mapped

to

MOBP,

including

rs1768208,

relate

to

regional

neurodegeneration in patients with sporadic forms of FTD and shorter survival in
FTD patients with underlying tau or TDP-43 pathology (Irwin, McMillan, et al.
2014; McMillan et al. 2014). Our group has also demonstrated an additive doseresponse relationship between the minor allele of rs12608932 (D’) in UNC13A
and in vivo cortical thinning in the dorsal prefrontal cortex, greater burden of
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TDP-43 pathology in the middle frontal and motor cortices at autopsy, and worse
performance on a measure of working memory associated with executive
function (Placek et al. 2019). rs538622 near ERGIC1, originally identified through
conditional FDR as a shared risk locus for ALS and FTD, has also been
previously demonstrated to contribute to quantitative trait modification in ALS by
relating to reduced expression of the protein BNIP1 in ALS patient motor neurons
(Karch et al. 2018). Other top-weighted variants near NSF and ATXN3 indicate
potential biological plausibility: rs10143310 is found near ATXN3 which encodes
a de-ubiquitinating enzyme, and polyglutamine expansions in ATXN3 cause
spinocerebellar ataxia – type 3 (Burnett, Li, and Pittman 2003). rs7224296 near
NSF tags the MAPT H1 haplotype (Yokoyama et al. 2017) and is associated with
increased risk for FTD syndromes including progressive supranuclear palsy and
corticobasal degeneration (Ferrari et al. 2017), as well as Alzheimer’s and
Parkinson’s diseases (Desikan et al. 2015).
While the mechanism of polygenic contribution to cognitive dysfunction in
ALS requires further investigation, we speculate based on our findings that
identified SNPs may contribute to neuroanatomic disease burden. A weighted
polygenic risk score derived from the observed multivariate genotype-phenotype
correlation in the CReATe PGB cohort showed robust relationships in
independent validation cohorts to both in vivo cortical thinning and post-mortem
cortical neuronal loss. Anatomically, these findings were largely consistent with
prior in vivo structural imaging studies of neurodegeneration associated with
cognitive dysfunction and with ex vivo investigations of cortical thinning in ALS
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(Lulé et al. 2018; Agosta et al. 2016; Prudlo et al. 2016). Thus, in addition to
indicating polygenic contribution to cognitive dysfunction in ALS, our findings
suggest a possible mechanism of observed findings via disease pathophysiology.
Beyond the potential biological mechanism of identifying polygenic contributions
to ALS disease heterogeneity, we additionally suggest that sCCA may provide
a tool for defining polygenic factors of disease risk. While sCCA has been widely
applied to imaging-genetic studies (Parkhomenko, Tritchler, and Beyene 2009),
we are unaware of prior applications using sCCA to define and polygenic
score based on rich clinical phenotypic and biomarker data. Traditional
approaches to the generation of polygenic scores include using data from
established, typically case-control GWAS, but practical considerations involve the
selection of how many variants to include in a model and how to define the
weights of an appropriate statistical model (Sugrue and Desikan 2019). Critically,
rather than an arbitrary selection of variants and their weights, the sparsity
parameter of sCCA facilitates an unsupervised, data-driven method to select the
number of variants to include in the model and the canonical correlation provides
data-driven weights to define the statistical model. The positive or negative
direction of model-derived weights is potentially biologically informative, and
could reflect ‘risk’ (i.e. positive weight) or ‘protective’ (i.e. a negative weight)
effects. Further investigation is necessary to clarify the relationships between
model-selected SNPs and model-derived canonical weight from both biological
(e.g., some SNPs and/or genes may contribute more strongly to risk factors) and
mathematical (e.g. weights may be constrained by minor allele frequency)
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perspectives. Nonetheless, sCCA may provide an optimal method for future
studies of polygenic variation and direct research efforts towards model-selected
variants.
Several limitations should be considered in the present study. Here, we
focus our analysis on a hypothesized relatively small set of SNPs selected a
priori from previous large-scale GWAS based on genome-wide association with
ALS (Nicolas et al. 2018) or shared risk between ALS and FTD (Karch et al.
2018). Other genetic variants not included in the present study may also
contribute to cognitive dysfunction in ALS and related disorders, and future
genome-wide or more broad genotype selection strategies (e.g., targeted
pathways) are necessary to elucidate discovery of novel genetic contributions to
cognition that have not been identified through prior case-control studies.
However, since our focused SNP selection targets previously validated
genotypes from GWAS studies, these larger scale studies necessitate further
validation in independent cohorts, many of which are lacking the rich phenotype
data needed to identify cognitive dysfunction. We derived a weighted polygenic
score from bootstrap

sCCA

modeling to further investigate

polygenic

associations with longitudinal clinical and cognitive performance, and to
investigate polygenic associations with in vivo and post-mortem disease
neuroanatomy in independent ALS cohorts from the UPenn Biobank. While we
define our polygenic score from sCCA using adjusted estimates of baseline
cognitive and motor performance, future work using longitudinal data as the
starting point to define polygenic associations may further elucidate genetic risk
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for cognitive dysfunction in ALS. However, our finding that polygenic risk
associated with baseline cognitive dysfunction also relates to longitudinal
cognitive decline in the PGB cohort and relevant disease anatomy in
independent cohorts suggests its relevance to longitudinal cognitive phenotypes
in ALS. Previous critique of polygenic scores suggest calculation based on
GWAS-defined odds ratios for univariate risk loci or undue influence by
population variance limit their use in clinical and prognostic settings (Wald and
Old 2019). To avoid these potential confounds, our computation of a weighted
polygenic risk score is based on model-selected parameters derived from an
analysis including all genetic variants and covariates for genetic mutation status
and sex in an effort to account for multivariate genetic relationships. We also
included the first two principal components in our model from a PCA conducted
in the PGB CReATe cohort in an effort to account for differences in population
heterogeneity (Price et al. 2006).
Our analyses focused on the investigation of genetic contribution to
cognitive dysfunction in ALS, yet it is well established that behavioral impairment
is also part of the ALS spectrum disease (Lillo et al. 2010). Further research is
necessary to investigate polygenic risk for behavioral dysfunction in ALS, and
whether loci included in our calculated polygenic score confer risk for both
cognitive and behavioral dysfunction. While this study demonstrates converging,
multimodal evidence for polygenic risk in independent neuroimaging and autopsy
cohorts, replication in additional, large cohorts that allow for robust crossvalidation is warranted, however, alternative datasets that contain detailed
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genetic and cognitive phenotyping for ALS are currently lacking, and the CReATe
PGB cohort represents the largest of its kind. Future research investigating
additional, large-scale patient cohorts with genetic and phenotypic data is
necessary.
With these limitations in mind, our research demonstrates converging
clinical, neuroimaging, and pathologic evidence for polygenic contribution to
cognitive dysfunction and cortical neurodegeneration in ALS. These findings
should stimulate further investigation into polygenic risk for cognitive disease
vulnerability in ALS and suggest their importance in prognostic consideration and
treatment trials. More broadly, this work provides insight into genetic contribution
to heterogeneous phenotypes in neurodegenerative disease and supports
evidence for polygenic architecture in these conditions.

Methods
Participants: CReATe Consortium
Participants consisted of 339 individuals clinically diagnosed by a board-certified
neurologist with a sporadic or familial form of amyotrophic lateral sclerosis (ALS),
amyotrophic

lateral

sclerosis

with

frontotemporal

dementia

(ALS-FTD),

progressive muscular atrophy (PMA), or primary lateral sclerosis (PLS) who were
enrolled and evaluated through the CReATe Consortium’s Phenotype-GenotypeBiomarker (PGB) study. All participants provided written informed consent. The
PGB study is registered on clinicaltrials.gov (NCT02327845) and the University
of Miami IRB (the central IRB for the CReATe Consortium) approved the study.
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This study entails participant blood DNA samples available for genetic screening
and longitudinal evaluation at regularly-scheduled visits (ALS, ALS-FTD, and
PMA: 0 (baseline), 3, 6, 12, and 18 months; PLS: 0 (baseline), 6, 12, 18, and 24
months). Participants were evaluated at each visit using the ALSFRS-R
(Cedarbaum, Stambler, Malta, Fuller, Hilt, Thurmond, and Nakanishi 1999b) and
alternate versions of the Edinburgh Cognitive and Behavioural ALS Screen
(ECAS) (Abrahams et al. 2014). Upper motor neuron (UMN) and lower motor
neuron (LMN) burden scores were calculated from a detailed elemental
neuromuscular examination by summing within and across each spinal region
resulting in a score ranging from 0 (none) to 10 (worst). Site (e.g. limb, bulbar)
and date of motor symptom onset were recorded for each participant. We
excluded nine individuals with missing or incomplete data that precluded
subsequent analysis and, in an effort to avoid confounds associated with clear
outliers, three individuals with extreme values at baseline on the ECAS
Visuospatial Score (i.e. >5 standard deviations from group mean), resulting in a
total of 327 participants. Of the nine excluded individuals with missing or
incomplete data, one had no genotyping data available, one had no information
for UMN burden, and seven had no information for date of motor symptom onset.

Genotyping: CReATe Consortium
Peripheral blood mononuclear cell DNA was extracted using the QIAamp DNA
Blood Mini Kit Qiagen #51106 and quantified using the Quant-iT dsDNA Assay
Kit (Life Technologies cat#Q33130). The DNA integrity was verified by agarose
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gel electrophoresis (E-Gel, Life Technologies, cat#G8008-01). Unique samples
were barcoded and whole genome sequencing (WGS) was performed at the
HudsonAlpha

Institute

for

Biotechnology

Genomic

Services

Laboratory

(Huntsville, Alabama) (HA) using Illumina HiSeq X10 sequencers to generate
approximately 360 million paired-end reads, each 150 base pairs (bp) in length.
Peripheral DNA was extracted from participant blood samples and screened for
known pathogenic mutations associated with ALS and related diseases.
Screening included repeat-primed PCR for C9ORF72 repeat expansions
and WGS curated and validated via Sanger sequencing for pathogenic mutations
associated with ALS and/or FTD in ANG, CHCHD10, CHMP2B, FUS, GRN,
hnRNPA1, hnRNPA2B1, MAPT, MATR3, OPTN, PFN1, SETX, SOD1, SPG11,
SQSTM1, TARDBP, TBK1, TUBA4A, UBQLN2, VCP. The PGB study also
includes patients with hereditary spastic paraplegia (HSP) that were excluded in
the current analysis, but we additionally screened individuals for pathogenic
mutations in 67 additional genes associated with HSP and seven genes
associated with distal hereditary motor neuropathy.
Whole genome sequencing (WGS) data were generated using paired-end
150 bp reads aligned to the GRCh38 human reference using the BurrowsWheeler Aligner (BWA-ALN v0.7.12)(Heng Li and Durbin 2010) and processed
using the Genome Analysis Toolkit (GATK) best-practices workflow implemented
in GATK v3.4.0 (McKenna et al. 2010). Variants for individual samples were
called with HaplotypeCaller, producing individual variant call format files (gVCFs)
that we combined using a joint genotyping step to produce a multi-sample VCF

(pVCF).

Variant

filtration

was

performed

using

Variant

Quality
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Score

Recalibration (VQSR), which assigns a score to each variant and a pass/fail label
and evaluated this in the context of hard filtering thresholds (Minimum Genotype
Quality (GQ)≥ 20, minimum mean depth value (DP)≥ 10). Variant annotation was
performed using Variant Effect Predictor (VEP) (Hunt et al. 2018) and in-house
pipelines including non-coding variant allele frequencies from Genome
Aggregation Database (gnomAD).(Karczewski et al. 2019) In-house scripts were
used to identify false positives resulting from paralogous mapping or/and gaps in
the current human genome assembly. VCFs were further decomposed prior to
analyses using the Decompose function of Vt (Tan, Abecasis, and Kang 2015).
To control for population substructure, we additionally derived the first two
principal components scores for each in the CReATe PBG cohort using principal
components analysis (PCA) as implemented in Eigenstrat software (Price et al.
2006).
From the WGS data we extracted 45 hypothesized variants from WGS
that previously achieved genome-wide significance for association with ALS
(Nicolas et al. 2018) or joint association with ALS and FTD via GWAS (Karch et
al. 2018). Proxy loci were genotyped (linkage disequilibrium (LD) R 2 > 0.80)
when genetic data were not available for previously-published loci. One locus,
rs12973192, was common to both references, and another locus (rs2425220
(Karch et al. 2018)) was excluded from analysis due to high level of missingness
across samples; no LD proxy was identified. We then used Plink software
(Purcell et al. 2007) to recode participant genotypes according to additive genetic
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models (e.g. 0 = no minor allele copies, 1 = one minor allele copy, 2 = two minor
allele copies), since the dominant or recessive nature of the loci included in this
study remains unknown.

Linear Mixed-Effects Modeling of the ECAS and clinical measures
We conducted linear mixed-effects modeling of performance on the ECAS,
ALSFRS-R, and UMN and LMN scores using the nlme package in R. Each
model was fit using maximum likelihood. In addition to the ECAS Total Score, we
analyzed Executive Function, Language, Verbal Fluency, Memory, and
Visuospatial scores and summary scores (ALS-Specific score, ALS-Non-Specific
score) each as dependent variables to analyze patient performance in separate
cognitive domains and in clinically-grouped cognitive domains. Fixed effects
included age at baseline visit (in years), lag between age of symptom onset and
age at baseline visit (in years), college education (yes / no), bulbar onset (yes /
no) and visit time-point (in months), and we included individual by visit time-point
as random effects. This allowed us to obtain adjusted estimates of baseline
performance (i.e. intercept) and rate of decline (i.e. slope) per individual, having
regressed out potential confounding variables as fixed effects.
We conducted Spearman’s rank-order correlations between baseline
performance and rate of decline using a Bonferroni family-wise error correction
for multiple comparisons.

Sparse Canonical Correlation Analysis
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We next conducted sparse canonical correlation analysis (sCCA) to select a
parsimonious linear combination of variables that maximize the correlation
between two multivariate datasets using the PMA package in R (Witten,
Tibshirani, and Hastie 2009). The first dataset comprised scaled intercepts from
each clinical variable per participant (i.e. adjusted baseline performance on the
ALSFRS-R, UMN and LMN assessments, and ECAS). The second comprised
minor allele counts per individual for each of the 45 SNPs (e.g. 0 = no minor
allele copies, 1 = one minor allele copy, 2 = two minor allele copies), binary
variables for sex (0 = Female, 1 = Male), C9ORF72 repeat expansion status (0 =
noncarrier, 1 = carrier), and other mutation status (0 = noncarrier, 1 = carrier)
and, in an effort to account for potential population differences in population
variance we also included the raw estimates for the first two principle
components per participant derived from a PCA conducted in the CReATe PGB
cohort, which has previously been demonstrated to account for the majority of
population structure (Price et al. 2006).
We assumed standard (e.g. unordered) organization of each dataset, and
selected regularization parameters for the sCCA analysis using a grid search of
100 combinations of L1 values between 0 (most sparse) and 1 (least sparse) in
increments of 0.1. We selected the combination of L1 values yielding the highest
canonical correlation of the first variate for subsequent analysis, as similarly
reported (Xia et al. 2018).
Using these L1 parameters, we ran 10,000 bootstrap sCCAs and on each
iteration employed randomly-generated subsamples comprising 75% of the PGB
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cohort. From this, we calculated the median canonical correlation for sCCA and
the median canonical weights for each variable. We utilize the median in these
estimates rather than the maximum or mean value in an effort to avoid bias from
outliers and to increase the reliability and reproducibility of model estimates.
We next investigated model performance under a null hypothesis (i.e. no
association between clinical and genetic datasets) by using randomly-permuted
data. Using the same L1 parameters, we again ran 10,000 bootstrap sCCAs and
on each iteration employed randomly-generated subsamples of 75% of
participants; however, on each iteration we randomly permuted each dataset 100
times using the randomizeMatrix function from the picante package in R. We
calculated a p value by reporting the probability of observing a canonical
correlation greater than or equal to the median canonical correlation under sCCA
modeling of the true data relative to the canonical correlations observed under
null sCCA modeling of randomly permuted data. We also examined the
proportion (i.e. out of 10,000) of times each variable was selected by the model
(i.e. achieving a non-zero canonical weight) under true and null modeling.

Polygenic Score
To evaluate the applicability of our sCCA model, we used the output of the model
to calculate a weighted polygenic score (wPGS) for each individual by computing
a weighted sum of allele dosage across all genotypes for each individual.
Weights were derived for each genetic variable by using the median canonical
weight over the 10,000 bootstrap sCCAs.
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To investigate construct validity, we conducted Spearman’s rank-order
correlations between the wPGS and adjusted estimates of baseline performance
(i.e. LME-derived intercepts) on the most frequently selected clinical measure(s)
selected from sCCA.
To investigate longitudinal performance associated with the wPGS, we
conducted Spearman’s rank-order correlations between the wPGS and adjusted
rates of decline (i.e. LME-derived slopes) on all clinical measures using a
Bonferroni familywise error correction for multiple comparisons. We restricted this
analysis to CReATe participants with data at 2 or more timepoints (N=277 out of
327 participants), or 84.7% of the participant cohort.

Participants: UPenn Biobank neuroimaging cohort
We retrospectively evaluated 114 patients with ALS and 114 healthy controls
matched for age, sex, and education from the UPenn Biobank who were
recruited for research between 2006 and 2019 from the Penn Comprehensive
ALS Clinic and Penn Frontotemporal Degeneration Center (Table 10) (Toledo et
al. 2014). Inclusion criteria for ALS patients consisted of complete genotyping at
analyzed SNPs, white non-Latino racial and ethnic background (population
diversity is known to influence allele frequencies across individuals), disease
duration from symptom onset < 2.5 standard deviations from respective group
means (to avoid confounds associated with clear outliers), and T1-weighted MRI.
All patients were diagnosed with ALS by a board-certified neurologist (L.E., L.M.,
M.G., D.I) using revised El Escorial criteria (Brooks et al. 2000) and assessed for
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ALS frontotemporal spectrum disorder using established criteria (Strong et al.
2017); those patients enrolled in research prior to 2017 were retrospectively
evaluated through chart review. All ALS patients and healthy controls participated
in an informed consent procedure approved by an Institutional Review Board
convened at UPenn.

Participants: UPenn Biobank autopsy cohort
We evaluated brain tissue samples from 88 ALS autopsy cases identified from
the UPenn Biobank (Toledo et al. 2014) who were diagnosed by a board-certified
neuropathologist (J.Q.T., E.B.L.) with ALS due to TDP-43 pathology using
immunohistochemistry (Neumann et al. 2006) and published criteria (Mackenzie
et al. 2011); this cohort included 21 patients from the ALS neuroimaging cohort.
Inclusion criteria consisted of complete genotyping at analyzed SNPs, white nonLatino racial and ethnic background (population diversity is known to influence
allele frequencies across individuals), disease duration from symptom onset <
2.5 standard deviations from respective group means (to avoid confounds
associated with clear outliers), and brain tissue samples from the middle frontal,
motor, cingulate, and superior / temporal cortices, and the cornu ammonis 1
(CA1) / subiculum of the hippocampus for analysis of neuronal loss and TDP-43
pathology. Nine individuals were missing neuronal loss or TDP-43 pathology data
for at least 1 sampled region (Table 13).

Genetic Screening and SNP Genotyping: UPenn Biobank
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DNA was extracted from peripheral blood or frozen brain tissue following the
manufacturer’s protocols (Flexigene (Qiagen) or QuickGene DNA whole blood kit
(Autogen) for blood, and QIAsymphony DNA Mini Kit (Qiagen) for brain tissue).
All patients were screened for C9ORF72 hexanucleotide repeat expansions
using a modified repeat-primed polymerase-chain reaction (PCR) as previously
described (Suh et al. 2015). Of the remaining individuals, we evaluated family
history using a 3-generation pedigree history as previously reported (Wood et al.
2013). For cases with a family history of the same disease we sequenced 45
genes previously associated with neurodegenerative disease, including genes
known to be associated with ALS (e.g. SOD1 (D. R. Rosen et al. 1993), TBK1
(Freischmidt et al. 2015)). Sequencing was performed using a custom-targeted
next-generation sequencing panel (MiND-Seq) (Toledo et al. 2014) and analyzed
using Mutation Surveyor software (Soft Genetics, State College, PA).
For analyses of UPenn Biobank samples, we genotyped peripheral or
brain cerebellum DNA of each case using the Illumina Infinium Global Screening
Array through the Children’s Hospital of Philadelphia (CHOP) Center for Applied
Genomics Core according to manufacturer’s specifications. PLINK (Purcell et al.
2007) was then used to remove variants with <95% call rate, Hardy-Weinberg
equilibrium (HWE) p-value < 10-6 and individuals with >5% missing genotypes.
Using the remaining genotypes from samples passing quality control, we
performed genome-wide imputation of allele dosages with the Haplotype
Reference Consortium reference panel r1.1 (McCarthy et al. 2016) on the
Michigan Imputation Server (Das et al. 2016) to predict genotypes at
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ungenotyped genomic positions, applying strict pre-phasing, pre-imputation
filtering, and variant position and strand alignment control.

Neuroimaging Processing and Analyses
High-resolution T1-weighted MPRAGE structural scans were acquired for
neuroimaging participants using a 3T Siemens Tim Trio scanner with an 8channel head coil, with T=1620ms, T=3.09ms, flip angle=15°, 192x256 matrix,
and 1mm3 voxels. T1-weighted MRI images were then preprocessed using
Advanced Normalization Tools (ANTs) software (Tustison et al. 2014). Each
individual dataset was deformed into a standard local template space in a
canonical stereotactic coordinate system. ANTs provide a highly accurate
registration routine using symmetric and topology-preserving diffeomorphic
deformations to minimize bias toward the reference space and to capture the
deformation necessary to aggregate images in a common space. Then, we used
N4 bias correction to minimize heterogeneity (Tustison et al. 2010) and the ANTs
Atropos tool to segment images into six tissue classes (cortex, white matter,
cerebrospinal fluid, subcortical grey structures, brainstem, and cerebellum) using
template-based priors and to generate probability maps of each tissue. Voxelwise cortical thickness was measured in millimeters (mm 3) from the pial surface
and then transformed into Montreal Neurological Institute (MNI) space, smoothed
using a 3 sigma full-width half-maximum Gaussian kernel, and downsampled to
2mm isotropic voxels.
We used randomise software from FSL to perform nonparametric,
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permutation-based statistical analyses of cortical thickness images from our
neuroimaging cohort. Permutation-based statistical testing is robust to concerns
regarding multiple comparisons since, rather than a traditional assessment of two
sample distributions, this method assesses a true assignment of factors (e.g.
wPGS) to cortical thickness relative to many (e.g., 10,000) random assignments
(Winkler et al. 2014).
We first identified reduced cortical thickness in ALS patients relative to
healthy controls. We constrained analysis using an explicit mask restricted to
high probability cortex (>0.4) and report clusters that survive p<0.05 thresholdfree cluster enhancement (TFCE) (Smith and Nichols 2009) corrected for familywise error relative to 10,000 random permutations.
We next evaluated whether wPGS relates to magnitude of reduced
cortical thickness, covarying for age, disease duration, and scanner acquisition in
an effort to control for factors associated with reduced cortical thickness but not
specifically associated with polygenic risk. We constrained analysis to an explicit
mask including regions of reduced cortical thickness identified relative to healthy
controls (see above). We report clusters that survive uncorrected p<0.01 with a
cluster extent threshold of 10 voxels relative to 10,000 random permutations; we
employ an uncorrected threshold to minimize the chance of Type II error (not
observing a true result).

Neuropathology Processing and Analyses
Extent of neuronal loss and of phosphorylated TDP-43 intraneuronal inclusions
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(dots, wisps, skeins) in sampled regions from the middle frontal, cingulate, motor,
and superior / middle temporal cortices, and the CA1 / subiculum of the
hippocampus were assessed on a semi-quantitative ordinal scale: 0=none/rare,
1=mild, 2=moderate, 3=severe/numerous. All neuropathological ratings were
performed by an expert neuropathologist (J.Q.T., E.B.L.) blinded to patient
genotype. We conducted ordinal logistic regression using the MASS package in
R to investigate whether extent of neuronal loss rated using Hematoxylin and
eosin (H&E) and burden of TDP-43 pathology rated using mAbs p409/410 or 171
(Lippa et al. 2009; Neumann et al. 2009) immunohistochemistry differed
according to wPGS, covarying for age and disease duration.
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Table 9: Demographics of ALS patients from the Phenotype-Genotype
Biomarker study of the CReATe Consortium.
ALS
279
163 (58.4)

ALS-FTD
13
11 (84.6)

PLS
22
11 (50.0)

PMA
13
8 (61.5)

3.09 (1.37)

3.00 (1.15)

2.86 (1.28)

3.38 (1.45)

56.32 (12.56)

64.00 (9.11)

49.68 (7.39)

48.08 (15.31)

3.59 (4.98)

3.62 (2.63)

8.45 (6.12)

7.77 (7.17)

45 (17.1)
7 (2.7)
7 (2.7)
175 (66.5)
22 (8.4)
7 (2.7)

4 (33.3)
1 (8.3)
3 (25)
4 (33.3)

5 (22.7)
3 (13.6)
13 (59.1)
1 (4.5)
-

11 (84.6)
1 (7.7)
1 (7.7)

196 (71.3)
34 (12.2)
22 (7.9)
1 (0.4)
8 (2.9)
1 (0.4)
1 (0.4)
1 (0.4)

9 (69.2)
3 (20.0)
3 (20.0)
-

20 (90.9)
0 (0.0)
-

10 (76.9)
0 (0.0)
-

35.00 (7.09)

35.00 (5.99)

36.50 (5.95)

33.62 (7.83)

2.70 (1.68)

2.45 (2.00)

4.54 (1.33)

0.87 (0.73)

2.54 (1.48)

2.81 (1.76)

0.59 (0.96)

4.84 (1.93)

ALS Specific (0-100)
Language (0-28)
Verbal Fluency (0- 24)
Executive (0-48)

80.94 (10.85)
25.85 (2.66)
16.62 (5.11)
38.47 (5.94)

52.62 (12.07)
21.38 (3.93)
7.83 (5.36)
24.00(10.51)

87.95 (7.47)
26.82 (1.97)
26.82 (1.97)
26.82 (1.97)

81.62 (11.61)
26.62 (1.26)
16.77 (4.36)
38.23 (7.50)

ALS Non-Specific (0-36)
Memory (0-24)
Visuospatial (0- 12)

28.04 (3.78)
16.45 (3.54)
11.59 (0.79)

19.69 (8.30)
9.46 (7.15)
11.08 (1.24)

29.73 (2.76)
17.95 (2.84)
11.77 (0.43)

27.62 (6.31)
15.69 (6.20)
11.92 (0.28)

108.97 (13.02)

72.31 (18.53)

117.68 (9.12)

109.23 (16.47)

N
Sex, Male (%)
Number of Visits,
Mean (SD)
Age at Symptom Onset,
Mean (SD)
Symptom Onset to Baseline
(years), Mean (SD)
Site of Symptom Onset, N (%)
Bulbar
Bulbar & Limb
Bulbar & Other
Limb
Limb & Other
Other
College Education or greater,
N (%)
Mutation Carrier, N (%)
C9ORF72
C9ORF72 and UBQLN2
SOD1
SQSTM1
TARDBP
TBK1
Baseline ALSFRS-R (0-48),
Mean (SD)
UMN Score (0-10),
Mean (SD)
LMN Score (0-10),
Mean (SD)
ECAS, Mean (SD)

ECAS Total (0-136)

Abbreviations: CReATe = Clinical Research in ALS and Related Disorders for
Therapeutic Development; PLS = Primary lateral sclerosis, PMA = Progressive
muscular atrophy; ALSFRS-R = Revised ALS Functional Rating Scale; UMN =
upper motor neuron; LMN = lower motor neuron; ECAS = Edinburgh Cognitive
and Behavioral ALS Screen; SD = standard deviation
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Table 10. Demographics of independent neuroimaging and autopsy ALS and
control cohorts from UPenn.
A. Neuroimaging Cohort
ALS

Healthy Control

N (Male)

114 (64)

114 (64)

Age at MRI in Years, M (SD)
Education in Years, M (SD)
Disease Duration in Years, M
(SD)
Mutation Carrier, N (%)
C9ORF72
SOD1
VCP
Site of Symptom Onset, N (%)
Bulbar
Limb
Cognitive
ALSFRS-R, M (SD)

59.34 (10.92)
15.09 (2.98)

61.87 (12.18)
15.87 (2.47)

3.02 (2.52)

-

14 (12.28)
1 (0.87)
1(0.87)

-

26 (22.81)
79 (69.3)
9 (7.89)
33.23 (7.32)

-

B. Autopsy Cohort
N (Male)

88 (49)

Age at Death Years, M (SD)
Disease Duration at Death in Years, M (SD)
Mutation Carrier, N (%)
C9ORF72
Site of Symptom Onset, N (%)
Bulbar
Limb
Cognitive
Respiratory
Unknown

63.72 (10.24)
4.24 (3.41)
15 (17.04)
23
60
3
1
1

Abbreviations: ALSFRS-R = ALS Functional Rating Scale – Revised; M = Mean,
SD = standard deviation
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Table 11: List of genetic variants analyzed.
1000
Marker Name Nearest Gene Chr Genome
GMAF

GRCh38 Position Proxy Marker Proxy HG19 Position

rs2068667

NFASC

1

0.208

chr1:204948552

rs11240317

chr1:204920322

rs11185393

AMY1A

1

0.368

chr1:104209379

rs67205957

chr1:104752258

rs515342

ASB1

2

0.214

chr2:238458655

rs508986

chr2:239337691

rs9820623

MOBP

3

0.406

chr3:39452367

rs6765697

chr3:39493239

rs13079368

MOBP

3

0.275

chr3:39471060

rs1464047

chr3:39526874

rs1768208

MOBP

3

0.323

chr3:39481512

rs616147

chr3:39534481

rs10463311

TNIP1

5

0.431

chr5:151031274

-

-

rs3828599

GPX3

5

0.417

chr5:151022235

rs4958872

chr5:150402334

rs538622

ERGIC1

5

0.32

chr5:172920676

rs2446192

chr5:172352369

rs17111695

NAF1

5

0.183

chr5:151052885

rs12518386

chr5:150438085

rs757651

REEP2

5

0.016

chr5:138455779

rs149312547

chr5:137792021

rs10488631

TNPO3

7

0.059

chr7:128954129

rs12539741

chr7:128596805

rs17070492 LOC101927815

8

0.208

chr8:2563763

-

-

rs7813314

BC045738

8

0.2

chr8:2558274

rs6996532

chr8:2417678

rs10869188

C9ORF72

9

0.49

chr9:72614090

rs7032232

chr9:75229116

rs870901

AK097706

9

0.133

chr9:107086201

rs60743641

chr9:109854824

rs10511816

MOBKL2B

9

0.206

chr9:27468463

rs12551344

chr9:27466817

rs3849943

C9ORF72

9

0.183

chr9:27543384

-

-

rs3849942

C9ORF72

9

0.183

chr9:27543283

-

-

rs13302855

C9ORF72

9

0.086

chr9:27595997

rs34460171

chr9:27594491

rs3849943

C9ORF72

9

0.183

chr9:27543384

-

-

rs732389

AK294518

10

0.205

chr10:78584745

rs7071538

chr10:80338173

rs7118388

CAT

11

0.454

chr11:34432600

rs1962369

chr11:34456941

rs12803540

CAT

11

0.138

chr11:34471200

rs17881488

chr11:34492443
-

rs117027576

KIF5A

12

0.00913

chr12:56922819

-

rs113247976

KIF5A

12

0.007

chr12:57581917

-

-

rs142321490

KIF5A

12

0.006

chr12:58282349

-

-

rs74654358

TBK1

12

0.012

chr12:64488187

-

-

rs118082508

KIF5A

12

0.005

chr12:5692503

-

-

rs116900480

KIF5A

12

0.006

chr12:58262322

-

-

rs1578303

HTR2A

13

0.204

chr13:47389011

rs144877054

chr13:47962781

rs10492593

PCDH9

13

0.121

chr13:66919985

rs73208976

chr13:67486924

rs17446243

TTL/TEL

13

0.116

chr13:40174794

rs78375967

chr13:40751567
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rs10139154

SCFD1

14

0.428

chr14:30678292

-

-

rs10143310

ATXN3

14

0.339

chr14:92074037

-

-

rs12886280

NUBPL

14

0.412

chr14:31829453

rs35875023

chr14:32298974

rs6603044

BTBD1

15

0.332

chr15:83015059

rs12904695

chr15:83700365
-

rs9901522

PMP22

17

0.18

chr17:14770617

-

rs739439

KIAA0524

17

0.105

chr17:28396803

rs35714695

chr17:26719788

rs2240601

MSI2

17

0.192

chr17:57673751

rs16942143

chr17:55748611

rs2285642

GGNBP2

17

0.407

chr17:36556904

rs10707226

chr17:34916453

rs7224296

NSF

17

0.472

chr17:46722680

rs9912530

chr17:44836302

rs12973192

UNC13A

19

0.278

chr19:17642430

-

-

rs12608932

UNC13A

19

0.43

chr19:17641880

rs12973192

chr19:17753239

rs4239633

UNC13A

19

0.28

chr19:17631660

rs71162163

chr19:17744075

rs75087725

C21orf72

21

0.003

chr21:44333234

-

-

Abbreviations: CReATe = Clinical Research in ALS and Related Disorders
for Therapeutic Development; GMAF = global minor allele frequency; Chr =
chromosome; GRCh38 = Genome Reference Consortium Human Build 38;
HG19 = Human Genome Project 19
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Table 12: Peak voxel coordinates for regions of reduced cortical thickness for
ALS relative to healthy controls and associated with increased weighted
polygenic score in patients with sporadic ALS from the independent validation
cohort from UPenn.
Neuroanatomic region (BA)

L/
R

MNI Coordinates
x
y
z

T
statistic

p
value

Voxels

1

Reduced cortical thickness in ALS relative to healthy controls :
<.001
Anterior cingulate cortex (32)

L

-2

48

10

7.2

Dorsolateral prefrontal cortex (9)

L

-2

48

18

7.08

Anterior premotor cortex (8)

L

-2

30

36

6.76

Orbitofrontal cortex (11)

R

8

26

-26

6.71

Insula (13)

R

40

16

-12

6.46

Insula (13)

R

36

22

4

6.37

Anterior prefrontal cortex (10)

R

26

58

0

6.32

Insula (13)

R

42

2

0

6.26

Dorsolateral prefrontal cortex (9)

R

2

48

18

6.22

Anterior cingulate cortex (32)

R

2

30

22

6

42994

Reduced cortical thickness associated with wPGS in ALS:
Lateral temporal cortex (21)

L

-66

-46

-8

3.01

0.003

34

Premotor cortex (6)

R

36

-14

70

3.05

0.001

23

Premotor cortex (6)

L

-14

-8

76

3

0.002

21

Orbital prefrontal cortex (47)

R

34

42

-8

2.67

0.005

18

Lateral temporal cortex (21)

L

-66

-44

6

2.54

0.002

13

Anterior cingulate cortex (32)

R

14

40

0

2.59

0.004

13

Hippocampus (54)

L

-24

-30

-8

2.74

0.004

10

Abbreviations: BA = Brodmann area; L/R = Left/Right; MNI = Montreal
Neurological Institute
Note.1 Cortical regions identified from peak voxel coordinates in an effort to
describe sub-peaks within a larger, contiguous cluster.
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Table 13: Number of UPenn ALS autopsy cases for each neuropathological
measurement in each sampled neuroanatomical region.
Region

Neuropathological
Measurement

N

Middle frontal cortex
Middle frontal cortex
Cingulate cortex
Cingulate cortex
Motor cortex
Motor cortex
Superior / middle temporal cortex
Superior / middle temporal cortex
CA1 / subiculum (hippocampus)
CA1 / subiculum (hippocampus)

Neuronal loss
TDP-43
Neuronal loss
TDP-43
Neuronal loss
TDP-43
Neuronal loss
TDP-43
Neuronal loss
TDP-43

87
87
88
87
84
86
87
84
88
85

Abbreviations: CA1 = cornu ammonis 1; TDP-43 = TAR DNA binding protein - 43
kiloDaltons
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Figure 6. Clinical and genetic heterogeneity in ALS patients from the CReATe
Phenotype-Genotype Biomarker study. A) Standard deviation from mean
baseline performance and rate of decline on each clinical variable for each
participant. B) Correlation matrix between baseline performance and rate of
decline on each clinical measure across all participants. C) Categorical coding for
each genetic variable for each participant (see next page).
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A

B

C
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Figure 7. Gridsearch for sparse canonical correlation analysis parameters. Each
column indicates 1 of 100 unique combinations of L1 parameters (ranging 0.1 to
1) applied to clinical and genetic datasets, and each row lists a variable entered
into the sCCA. The heatmap denotes the canonical weight strength between
clinical variables and genetic variables within each column; warmer colors
indicate positive weights and cooler colors indicate negative weights.
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Language
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Figure 8. 10,000 iterations of sparse canonical correlation analysis modeling
using bootstrapped subsampling. Each column indicates 1 of 10,000 iterations
from randomly-bootstrapped subsamples of 75% of participants in the CReATe
PGB cohort, and each row lists a variable entered into the sCCA. The heatmap
denotes the canonical weight strength for each clinical variables and genetic
variables within each column; warmer colors indicate positive weights and cooler
colors indicate negative weights.
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Figure 9. p value calculation for sparse canonical correlation analysis modeling.
Histogram showing the frequency of canonical correlations achieved for sCCA
modeling under the null hypothesis across 10,000 randomly bootstrapped sCCAs
of randomly permuted data. The vertical turquoise line demonstrates the median
canonical correlation achieved under sCCA modeling of the original, unpermuted
data, and the p value is calculated as the proportion of times the median
canonical correlation was achieved for sCCA modeling of randomly permuted
data.
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Figure 10. Sparse polygenic relationship between clinical and genetic variation in
ALS patients from the CReATe Phenotype-Genotype Biomarker study. sCCA
selected Edinburgh Cognitive and Behavioral ALS Screen (ECAS) subscores
and 29 genetic variables which resulted in the maximal correlation between
clinical and genetic variates in the CReATe PGB cohort. The color key denotes
which variables were selected for inclusion in the model: Green = selected, Gray
= not selected. The heatmap denotes the median canonical weight associated
with each relationship between each selected SNP and the ECAS Score, with
warmer colors indicative of positive weights and cooler colors indicative of
negative weights.
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Figure 11. Variables selected sparse canonical correlation analysis modeling
using original, unpermuted data and, under the null hypothesis, randomlypermuted data. A) Bar graphs demonstrating the proportion of times out of
10,000 randomly-bootstrapped sCCAs that each of the 11 clinical variables were
selected by sCCA using randomly permuted (turquoise) and original (coral) data.
B) Bar graphs demonstrating the number of times out of 10,000 randomlybootstrapped sCCAs that each of the 45 investigated SNPs were selected by
sCCA using randomly permuted (turquoise) and original (coral) data. SNPs are
organized according to prior genome-wide association with ALS or joint
association with ALS and FTD.
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Figure 12. Correlation between weighted polygenic risk score and cognitive
performance in ALS patients from the CReATe Phenotype-Genotype Biomarker
study. Weighted polygenic risk score correlates with A) adjusted baseline
performance on the Edinburgh Cognitive and Behavioral ALS Screen (ECAS)
ALS-Specific, Total, Executive Function, and Language scores, and B) rate of
decline on the ALS-Specific, ALS-NonSpecific, and Total scores.
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Figure 13. Cortical thickness and neuronal loss related to weighted polygenic
risk score in independent cohorts from UPenn.
A) ALS patients (N=114) from an independent cohort at UPenn displayed
widespread cortical thinning relative to age, sex, and education-matched healthy
controls (N=114) in the frontal and temporal lobes. The heatmap indicates the
associated T-statistic for each voxel, with light yellow representing the highest
value.

B) ALS patients (N=114) from an independent cohort at UPenn with higher
weighted polygenic risk score exhibited greater reduction of cortical thickness in
the orbital prefrontal cortex, anterior cingulate cortex, premotor cortex, lateral
temporal cortex, and hippocampus. The heatmap indicates the associated Tstatistic for each voxel, with light blue representing the highest value.
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C) Beeswarm boxplots of ordinal neuronal loss score (0 = none/rare, 3 = severe)
in ALS cases at autopsy from an independent cohort at UPenn (N=88) showing
that greater ordinal neuronal loss score is associated with higher weighted
polygenic risk score.
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CHAPTER 5
Research from the past several decades has demonstrated inextricable clinical,
biologic, and genetic linkage between ALS and FTD, such that the two diseases
are contemporarily conceptualized as occurring as clinical extremes on a
continuous spectrum. Affected individuals experience disease onset often in
middle age and diagnosis precedes death typically in less than 10 years. There is
no cure for disease, and current treatments are only palliative or disease-slowing
in nature. Despite advances in modern understanding of the cause and
consequence of ALS-FTD spectrum disease, profound phenotypic heterogeneity
precludes clinical prognostication and efforts for therapeutic development.
Critically, cognition is a major source of phenotypic heterogeneity and impaired
cognition confers increased risk for decreased functional ability during disease
course and shorter survival. The goal of my thesis work has been to elucidate
factors that influence cognition and underlying disease neuroanatomy in ALSFTD spectrum disease, with the ultimate goal of defining prognostic markers and
potential targets for disease-modifying therapies. In a series of three original
research studies, I demonstrate strong environmental and genetic contribution to
severity of cognitive impairment and frontotemporal disease neuroanatomy in
ALS-FTD spectrum disease.
In the first study, I show environmental contribution from lifetime cognitive
engagement to verbal executive control and gray matter atrophy in a
phenotypically and genetically diverse cohort of patients. Specifically, my results
indicate that higher education and occupation – considered singly or cumulatively
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in a cognitive reserve index – relate to reduced gray matter atrophy in rightlateralized prefrontal cortical regions functionally linked to executive processes,
and relate to less impaired performance on a measure of verbal executive
control. I further demonstrate through analysis of data from healthy controls that
this association is specific to patients. In answer to my first research question,
“How does lifetime cognitive engagement relate to cognition and disease
neuroanatomy in ALS-FTD spectrum disease?”, these findings suggest that
lifetime cognitive engagement contributes to heterogeneity of verbal executive
control and underlying neurodegeneration in functionally-associated prefrontal
cortical regions.
In the second study, I demonstrate converging, multimodal evidence that
common genetic variation at rs12608932 in UNC13A, a previously-identified risk
locus for ALS and FTD, further contributes to frontotemporal disease in patients
with sporadic ALS-FTD spectrum disease with initial ALS. My findings indicate
that patients carrying the rs12608932 minor allele exhibit more severe in vivo
cortical thinning in prefrontal, motor, and temporal cortices and greater
impairment on a measure of working memory under both additive and recessive
minor allele modeling. Consistent with in vivo findings, analyses in a separate
autopsy cohort show that carriers of the rs12608932 minor allele have greater
burden of post mortem TDP-43 pathology in the middle frontal cortex, middle
temporal cortex, and motor cortex. In answer to my second research question,
“Do common genetic variants that confer risk for ALS-FTD spectrum disease
relate to cognition and disease neuroanatomy?”, my results demonstrate
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converging multimodal evidence of contribution via common, single-allelic
genetic variation at rs12608932 to frontotemporal disease phenotype.
Last, in the third study, I demonstrate that common genetic variation further
contributes to cognition and underlying disease neuroanatomy in a polygenic
manner. Using machine learning conducted in a large, multicenter patient cohort,
I find polygenic contribution predominantly from SNPs conferring joint risk for
ALS and FTD to cognitive performance in ALS patients both at baseline and
longitudinally. I derive a polygenic risk score for cognitive dysfunction based on
these results, and show that ALS patients at higher polygenic risk have greater
cortical atrophy in the prefrontal, premotor, and temporal cortices and the
hippocampus. I further show in an independent autopsy cohort that ALS patients
at higher polygenic risk demonstrate more severe neuronal loss in the motor
cortex. In answer to the question, “Is there evidence of polygenic contribution via
common genetic variants to cognition and disease neuroanatomy?”, this study
provides quantitative trait evidence for polygenic contribution from common
genetic variants to cognition and frontotemporal disease neuroanatomy in ALSFTD spectrum disease.
Collectively, this body of work aids scientific understanding of factors
shaping heterogeneous cognitive phenotypes in ALS-FTD spectrum disease and
offers biomarkers for actionable use in patient prognostication and clinical trials.
In this final chapter, I now consider avenues for future research stemming from
my thesis work and conclude by remarking on the implications this work holds for
the field.
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Limitations & Future Directions
My thesis work motivates a number of avenues for future research on factors
contributing to heterogeneous phenotypes in ALS-FTD spectrum disease and
suggests methods applicable for similar study in other phenotypically
heterogeneous neurodegenerative diseases.
The work in this dissertation presents evidence in favor of strong
contribution from both lifetime cognitive engagement and common genetic
variation to cognition and disease neuroanatomy in ALS-FTD spectrum disease,
leading to a subsequent line of inquiry: Do these factors interact to influence
phenotypic heterogeneity? A few recent studies, while limited to patients with
FTD, suggest that such interaction may occur. Presymptomatic individuals either
positive for a pathogenic mutation in C9ORF72, MAPT, or GRN or with a strong
familial disease history display higher premorbid frontal and total GM volume
relating to greater educational attainment (Gazzina et al. 2019; Premi et al.
2017); interestingly, risk genotype at a SNP near TMEM106B was found to
enhance this relationship in mutation carriers relative to non-carriers (Premi et al.
2017). Another study in a symptomatic FTD cohort ranging in clinical phenotypes
and mutation status showed that risk genotype at a polymorphism near the
SCLA4 gene magnified the association between an index of lifetime cognitive
engagement and reduced frontal cerebral blood flow (Premi et al. 2015). With
these findings in mind, it is reasonable to surmise that similar interactions may
occur between lifetime cognitive engagement and common genetic variation at
single loci or considered in a polygenic manner. This train of thought could be
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further extended to examine potential interactions between genetic factors and
other environmental factors not specifically associated with lifetime cognitive
engagement, such as smoking (Sutedja et al. 2007), physical activity (Huisman
et al. 2013), and traumatic brain injury (Kalkonde et al. 2012; Rosso, Landweer,
et al. 2003), which have been associated with risk for ALS and FTD. In a similar
vein, epigenetic modification of genes associated with ALS and FTD (e.g.
C9ORF72 (McMillan et al. 2015; Russ et al. 2015)) could be also explored
relative to environmental factors. Thus, one avenue for future work is to examine
how environmental and genetic factors may interact or concurrently influence
cognition and disease anatomy across ALS-FTD spectrum disease.
A second logical extension of my thesis work regards the broader study of
genetic factors. I limited my investigation of common genetic variants in my
thesis work to loci previously identified as conferring risk for ALS and FTD to
explore quantitative-trait relationships with cognition and disease anatomy in a
hypothesis-driven manner. However, in recent years, whole-genome sequencing
has become increasingly cost-effective and technological advances have
enabled greater computational efficiency for the analysis of extremely large data
sets (e.g. 3.2 billion reads from ~38x genome coverage). Another interesting
avenue for further study is thus the study of the whole genome relative to
cognition and neuroanatomy in ALS-FTD spectrum disease. For example,
sparse, machine learning approaches like sCCA could investigate genotypephenotype
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(e.g. neuropsychological evaluation, voxel-wise neuroimaging data). Some
intriguing and innovative research studies over the past decade from the
Alzheimer’s disease literature offer insight into the potential use of genome-wide
data relative to complex quantitative phenotypes. These include the development
of a voxel-wise GWAS techniques designed to identify genetic loci associated
with regional heterogeneity in structural neuroimaging these methods has been
applied to identify both SNP-based and gene-based loci associated with brain
volume in healthy elderly participants and mixed cohorts of controls and patients
from ADNI (Stein et al. 2010; Hibar et al. 2011). More recent studies from the
Alzheimer’s disease literature also describe techniques for analyzing genomewide data relative to neuropathological categorization and relative to clinical
phenotypic variation (Beecham et al. 2014; Moreno-Grau et al. 2019). It is
therefore not unreasonable to suggest these techniques could be adopted to the
study of genetic factors influencing heterogeneity in cognition and disease
anatomy, ascertained through multiple modalities including neuropsychological
evaluation, neuroimaging, and post mortem neuropathological examination, in
ALS-FTD spectrum disease.
A third extension of the work presented here concerns the expansion of
data sources and the methods used to analyze them. Based on my defined
research questions, I chose to study data from symptomatic patients with ALSFTD spectrum disease and to use specific nonparametric and machine learning
methods. Other data sources, including from biofluid biomarkers (Benatar,
Turner, and Wuu 2019; van der Ende et al. 2019) and functional neuroimaging
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(Ferraro et al. 2018; Olm et al. 2018; Mutsaerts et al. 2019), reflect disease
processes in presymptomatic individuals with familial disease history or genetic
mutations. For example, serum and CSF levels of phosphorylated neurofilament
heavy (pNfH) and neurofilament light (NfL) increase longitudinally in advance of
clinically manifest ALS (Benatar et al. 2019). A potential future line of research
could thus investigate environmental and genetic factors relative to cognition and
frontotemporal disease anatomy in presymptomatic individuals. Results from this
proposed research in presymptomatic ALS-FTD could then be subsequently
investigated in symptomatic patient cohorts, with analyses stratified for mutationnegative and sporadic forms of disease. In addition to data sources reflecting
early disease stage, my thesis work could be extended to utilize other
unsupervised machine learning methods to identify genetic factors associated
with disease. These include methods integrating prior knowledge (e.g. GWAS
effect sizes for loci associated with disease risk) into model estimates (Blatti et al.
2020), and methods designed to identify quantitative trait loci associated with
data collected from patients with different disease groups (H. Wang et al. 2012).
In the context of ALS-FTD spectrum disease, such machine learning methods
could be used to integrate effect sizes from ALS and FTD GWAS into model
estimates of genetic risk for impaired cognition, and to identify loci associated
with multiple phenotypes (e.g. identify loci associated with impaired cognition and
frontotemporal atrophy).
A final avenue for future research stems from the ubiquitous need for
independent replication of scientific findings, including those presented in the
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current body of work. As noted in the introduction, I have endeavored to adopt
robust statistical approaches including the incorporation of multiple modalities in
an attempt to validate my findings across datasets, given the absence at the time
of study of additional, independent cohorts sufficient data necessary for true
replication. I have incorporated analysis of complementary, independent datasets
(e.g. from ADNI, the CReATe Consortium, and the UPenn Integrated
Neurodegenerative Disease Biobank) to evaluate null hypothesis in control
cohorts and seek converging evidence from additional biomarkers for my results,
when possible. Tremendous efforts for multicenter, cross-institutional, and
international observational research studies have been made through the recent
formation of entities including the CReATe consortium and the ARTFL–LEFFTDS
Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) research consortium
(H. J. Rosen, Boeve, and Boxer 2020). True replication of the environmental and
genetic influence on cognition and disease anatomy that I demonstrate through
my work will likely only be accomplished through continued support for and
research participation in these, and other, collaborative endeavors.

Conclusions and Implications for the Field
The research studies I have pursued for my thesis addressed the critical clinical
need for the identification of factors influencing heterogeneity in cognition and
disease anatomy in ALS-FTD spectrum disease. The availability of rich,
multimodal data from large patient cohorts was critical to my study design and to
the strength of evidence I was able to present in support of robust contribution
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from environmental and genetic factors to cognition and underlying disease
anatomy in ALS-FTD spectrum disease.
My thesis work holds implications for future advancements in clinical care and
therapeutic development and stimulates further research. The environmental and
genetic factors elucidated through my research hold potential to improve
prognostication in clinical care and therapeutic development with appropriate
validation. Routine patient genotyping, generated through a minimally-invasive
procedure in an increasingly cost-effective manner, may be used to investigate
pharmaco-genomic interactions in ongoing clinical trials. Patient genotyping and
measures of lifetime cognitive engagement (e.g. education and occupation) could
further be used to stratify patients in clinical trials to alleviate potential confounds
associated with the profound phenotypic heterogeneity observed in ALS-FTD
spectrum disease. In addition to stratification, environmental and genetic factors
might also serve as potential therapeutic targets. For example, cognitive
engagement and associated frontal cortical function might be targeted early in
disease course through digital (e.g. smartphone applications) or neuromodulatory
(e.g. transcranial direct current stimulation) strategies. With these clinical and
therapeutic implications in mind, my work stimulates future research on genetic
and environmental factors influencing heterogeneity in patient phenotype. My
work has demonstrated the critical utility of large, multimodal datasets in
elucidating disease-modifying factors, and accordingly implicates that further
support and maintenance of collaborative data-collection on patient populations
is necessary to conduct scientifically-rigorous and clinically-meaningful studies.
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